| Experimental Factor Ontology (EFO) Information | |
| Identifier | EFO_0000677 |
| Description | A disease that has its basis in the disruption of mental process. [MONDO: patterns/basis_in_disruption_of_process] | Trait category |
Neurological disorder
|
| Synonyms |
22 synonyms
|
| Mapped terms |
22 mapped terms
|
| Child trait(s) |
24 child traits
|
| Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
|---|---|---|---|---|---|---|
| PGS000025 (GRS) |
PGP000015 | Chouraki V et al. J Alzheimers Dis (2016) |
Alzheimer's disease | Alzheimer disease | 19 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000025/ScoringFiles/PGS000025.txt.gz |
| PGS000026 (PHS) |
PGP000016 | Desikan RS et al. PLoS Med (2017) |
Alzheimer's disease | Alzheimer disease | 33 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000026/ScoringFiles/PGS000026.txt.gz | |
| PGS000053 (ALZ21_NIA-LOAD) |
PGP000039 | Tosto G et al. Neurology (2017) |
Alzheimer's disease (late onset) | late-onset Alzheimer's disease | 21 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000053/ScoringFiles/PGS000053.txt.gz |
| PGS000054 (ALZ21_EFIGA) |
PGP000039 | Tosto G et al. Neurology (2017) |
Alzheimer's disease (late onset) | late-onset Alzheimer's disease | 21 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000054/ScoringFiles/PGS000054.txt.gz |
| PGS000133 (SCZ_BVU) |
PGP000065 | Zheutlin AB et al. Am J Psychiatry (2019) |
Schizophrenia | schizophrenia | 604,645 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000133/ScoringFiles/PGS000133.txt.gz |
| PGS000134 (SCZ_GHS) |
PGP000065 | Zheutlin AB et al. Am J Psychiatry (2019) |
Schizophrenia | schizophrenia | 830,589 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000134/ScoringFiles/PGS000134.txt.gz |
| PGS000135 (SCZ_MTS) |
PGP000065 | Zheutlin AB et al. Am J Psychiatry (2019) |
Schizophrenia | schizophrenia | 972,439 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000135/ScoringFiles/PGS000135.txt.gz |
| PGS000136 (SCZ_PBK) |
PGP000065 | Zheutlin AB et al. Am J Psychiatry (2019) |
Schizophrenia | schizophrenia | 833,502 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000136/ScoringFiles/PGS000136.txt.gz |
| PGS000138 (LifetimeMDD) |
PGP000068 | Cai N et al. Nat Genet (2020) |
Lifetime Major Depressive Disorder | major depressive disorder | 22,274 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000138/ScoringFiles/PGS000138.txt.gz |
| PGS000139 (MDDRecur) |
PGP000068 | Cai N et al. Nat Genet (2020) |
Lifetime Major Depressive Disorder (with recurrence) | recurrent, major depressive disorder |
21,980 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000139/ScoringFiles/PGS000139.txt.gz |
| PGS000140 (GPpsy) |
PGP000068 | Cai N et al. Nat Genet (2020) |
Broad Depression (seen a General Practitioner for nerves, anxiety, tension or depression) | seeing a general practitioner for nerves, anxiety, tension or depression, self-reported, depressive disorder |
24,665 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000140/ScoringFiles/PGS000140.txt.gz |
| PGS000141 (Psypsy) |
PGP000068 | Cai N et al. Nat Genet (2020) |
Seen a psychiatrist for nerves, anxiety, tension or depression | seeing a psychiatrist for nerves, anxiety, tension or depression, self-reported, depressive disorder |
22,728 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000141/ScoringFiles/PGS000141.txt.gz |
| PGS000142 (DepAll) |
PGP000068 | Cai N et al. Nat Genet (2020) |
Probable Depression (low mood or anhedonia, and seen a GP or psychiatrist for nerves, anxiety, tension or depression) | seeing a general practitioner for nerves, anxiety, tension or depression, self-reported, seeing a psychiatrist for nerves, anxiety, tension or depression, self-reported, depressive disorder |
21,908 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000142/ScoringFiles/PGS000142.txt.gz |
| PGS000145 (ICD10Dep) |
PGP000068 | Cai N et al. Nat Genet (2020) |
Depression (ICD-10 defined) | major depressive disorder | 21,510 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000145/ScoringFiles/PGS000145.txt.gz |
| PGS000193 (MDD_0.001_Coleman_2020) |
PGS000080 | Coleman JRI et al. Mol Psychiatry (2020) |
Major depression | major depressive disorder | 1,138 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000193/ScoringFiles/PGS000193.txt.gz |
| PGS000327 (ASD2019) |
PGP000098 | Grove J et al. Nat Genet (2019) |
Autism spectrum disorder | autism spectrum disorder | 35,087 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000327/ScoringFiles/PGS000327.txt.gz | |
| PGS000334 (GRSfull_22) |
PGP000101 | Zhang Q et al. Nat Commun (2020) |
Late-onset Alzheimer’s disease | late-onset Alzheimer's disease | 22 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000334/ScoringFiles/PGS000334.txt.gz |
| PGS000756 (GRS3_Nar) |
PGP000162 | Ouyang H et al. Ann Transl Med (2020) |
Narcolepsy | narcolepsy-cataplexy syndrome | 32 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000756/ScoringFiles/PGS000756.txt.gz |
| PGS000757 (GRS4_Nar) |
PGP000162 | Ouyang H et al. Ann Transl Med (2020) |
Narcolepsy | narcolepsy-cataplexy syndrome | 5 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000757/ScoringFiles/PGS000757.txt.gz |
| PGS000767 (GRS14) |
PGP000174 | Guffanti G et al. Transl Psychiatry (2019) |
Depression | depressive symptom measurement, major depressive disorder |
14 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000767/ScoringFiles/PGS000767.txt.gz |
| PGS000779 (PGS7_AD) |
PGP000183 | Zhou X et al. Alzheimers Dement (Amst) (2020) |
Alzheimer's disease | Alzheimer disease | 7 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000779/ScoringFiles/PGS000779.txt.gz | |
| PGS000811 (AD-PRS_39) |
PGP000196 | Najar J et al. Alzheimers Dement (Amst) (2021) |
Alzheimer's disease | Alzheimer disease | 39 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000811/ScoringFiles/PGS000811.txt.gz |
| PGS000812 (AD-PRS_57) |
PGP000196 | Najar J et al. Alzheimers Dement (Amst) (2021) |
Alzheimer's disease | Alzheimer disease | 57 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000812/ScoringFiles/PGS000812.txt.gz |
| PGS000823 (GRS23_AD) |
PGP000207 | van der Lee SJ et al. Lancet Neurol (2018) |
Alzheimer's disease | Alzheimer disease | 23 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000823/ScoringFiles/PGS000823.txt.gz |
| PGS000876 (PRS31_AD) |
PGP000222 | Leonenko G et al. Ann Clin Transl Neurol (2019) |
Alzheimer's disease | Alzheimer disease | 31 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000876/ScoringFiles/PGS000876.txt.gz |
| PGS000898 (PRS39_AD) |
PGP000231 | de Rojas I et al. Nat Commun (2021) |
Alzheimer's disease | Alzheimer disease | 40 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000898/ScoringFiles/PGS000898.txt.gz | |
| PGS000907 (PRS_MDD) |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Major depressive disorder | major depressive disorder | 1,773,528 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000907/ScoringFiles/PGS000907.txt.gz |
| PGS000908 (PRS_Insomnia) |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Insomnia | insomnia | 2,746,982 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000908/ScoringFiles/PGS000908.txt.gz |
| PGS000926 (GBE_QT_FC1001220) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Daytime dozing / sleeping (narcolepsy) | narcolepsy | 4,194 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000926/ScoringFiles/PGS000926.txt.gz |
| PGS000929 (GBE_HC1583) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
All-cause dementia (algorithmically-defined) | dementia | 6 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000929/ScoringFiles/PGS000929.txt.gz |
| PGS000945 (GBE_HC710) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Dementia in Alzheimer's disease (time-to-event) | dementia, Alzheimer disease |
26 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000945/ScoringFiles/PGS000945.txt.gz |
| PGS000946 (GBE_HC713) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Unspecified dementia (time-to-event) | dementia | 9 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000946/ScoringFiles/PGS000946.txt.gz |
| PGS001179 (GBE_HC711) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Vascular dementia (time-to-event) | vascular dementia | 7 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001179/ScoringFiles/PGS001179.txt.gz |
| PGS001348 (GBE_HC1584) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Alzheimer's disease (algorithmically-defined) | Alzheimer disease | 15 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001348/ScoringFiles/PGS001348.txt.gz |
| PGS001349 (GBE_HC807) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Alzheimer's disease (time-to-event) | Alzheimer disease | 6 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001349/ScoringFiles/PGS001349.txt.gz |
| PGS001775 (PRS39_AD) |
PGP000255 | Ebenau JL et al. Alzheimers Dement (Amst) (2021) |
Alzheimer's disease | Alzheimer disease | 39 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001775/ScoringFiles/PGS001775.txt.gz |
| PGS001827 (portability-PLR_290.1) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Dementia | dementia | 33 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001827/ScoringFiles/PGS001827.txt.gz |
| PGS001828 (portability-PLR_290.11) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Alzheimer's disease | Alzheimer disease | 38 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001828/ScoringFiles/PGS001828.txt.gz |
| PGS001829 (portability-PLR_296.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Depression | depressive disorder | 7,534 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001829/ScoringFiles/PGS001829.txt.gz |
| PGS001830 (portability-PLR_318) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Tobacco use disorder | nicotine dependence | 13,838 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001830/ScoringFiles/PGS001830.txt.gz |
| PGS001932 (portability-PLR_insomnia) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Sleeplessness / insomnia | insomnia | 37,712 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001932/ScoringFiles/PGS001932.txt.gz |
| PGS001995 (portability-PLR_narcolepsy) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Daytime dozing / sleeping (narcolepsy) | narcolepsy | 27,143 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001995/ScoringFiles/PGS001995.txt.gz |
| PGS002035 (portability-ldpred2_290.1) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Dementia | dementia | 39,752 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002035/ScoringFiles/PGS002035.txt.gz |
| PGS002036 (portability-ldpred2_296.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Depression | depressive disorder | 807,338 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002036/ScoringFiles/PGS002036.txt.gz |
| PGS002037 (portability-ldpred2_318) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Tobacco use disorder | nicotine dependence | 847,691 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002037/ScoringFiles/PGS002037.txt.gz |
| PGS002098 (portability-ldpred2_abnormal_appetite) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Recent poor appetite or overeating | eating disorder | 764,146 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002098/ScoringFiles/PGS002098.txt.gz |
| PGS002144 (portability-ldpred2_hard_falling_asleep) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Trouble falling asleep | Sleep Disorder | 539,784 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002144/ScoringFiles/PGS002144.txt.gz |
| PGS002149 (portability-ldpred2_insomnia) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Sleeplessness / insomnia | insomnia | 926,585 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002149/ScoringFiles/PGS002149.txt.gz |
| PGS002212 (portability-ldpred2_narcolepsy) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Daytime dozing / sleeping (narcolepsy) | narcolepsy | 893,802 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002212/ScoringFiles/PGS002212.txt.gz |
| PGS002249 (AD_PRS_0.5) |
PGP000276 | Lourida I et al. JAMA (2019) |
Alzheimer's disease | Alzheimer disease | 249,273 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002249/ScoringFiles/PGS002249.txt.gz |
| PGS002280 (GRS83_AD) |
PGP000309 | Bellenguez C et al. Nat Genet (2022) |
Alzheimer's disease | Alzheimer disease | 83 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002280/ScoringFiles/PGS002280.txt.gz |
| PGS002289 (GRS23_AD) |
PGP000316 | Zimmerman SC et al. JAMA Netw Open (2022) |
Late-onset Alzheimer's disease | late-onset Alzheimer's disease | 23 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002289/ScoringFiles/PGS002289.txt.gz |
| PGS002731 (oA-PRS) |
PGP000339 | Xicota L et al. Neurology (2022) |
Alzheimer's disease | Alzheimer disease | 17 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002731/ScoringFiles/PGS002731.txt.gz | |
| PGS002738 (PRS_AUD) |
PGP000345 | Lai D et al. Alcohol Clin Exp Res (2022) |
Alcohol use disorder | alcohol dependence | 326,000 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002738/ScoringFiles/PGS002738.txt.gz |
| PGS002739 (PRS_gene) |
PGP000346 | Lai D et al. Transl Psychiatry (2022) |
Alcohol use disorder | alcohol dependence | 858 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002739/ScoringFiles/PGS002739.txt.gz |
| PGS002746 (PRS_ADHD) |
PGP000358 | Lahey BB et al. J Psychiatr Res (2022) |
Attention-deficit hyperactivity disorder | attention deficit hyperactivity disorder | 513,659 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002746/ScoringFiles/PGS002746.txt.gz |
| PGS002753 (Alzheimer_s_disease_prscs) |
PGP000364 | Mars N et al. Am J Hum Genet (2022) |
Alzheimer's disease | Alzheimer disease | 1,092,011 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002753/ScoringFiles/PGS002753.txt.gz |
| PGS002759 (Depression_prscs) |
PGP000364 | Mars N et al. Am J Hum Genet (2022) |
Depression | major depressive disorder | 1,091,613 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002759/ScoringFiles/PGS002759.txt.gz |
| PGS002785 (SCZ_SDPR) |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Schizophrenia | schizophrenia | 964,422 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002785/ScoringFiles/PGS002785.txt.gz |
| PGS002786 (BD_SDPR) |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Bipolar disorder | bipolar disorder | 948,996 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002786/ScoringFiles/PGS002786.txt.gz |
| PGS002787 (BD1_SDPR) |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Type 1 bipolar disorder | bipolar I disorder | 937,511 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002787/ScoringFiles/PGS002787.txt.gz |
| PGS002788 (BD2_SDPR) |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Type 2 bipolar disorder | bipolar II disorder | 935,292 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002788/ScoringFiles/PGS002788.txt.gz |
| PGS002789 (MDD_SDPR) |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Major depressive disorder | major depressive disorder | 943,784 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002789/ScoringFiles/PGS002789.txt.gz |
| PGS002790 (ASD_SDPR) |
PGP000370 | Gui Y et al. Transl Psychiatry (2022) |
Autism spectrum disorder | autism spectrum disorder | 916,713 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002790/ScoringFiles/PGS002790.txt.gz |
| PGS003204 (ExPRSweb_SleepApnea_finngen-R4-G6-SLEEPAPNO_LASSOSUM_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 4,360 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003204/ScoringFiles/PGS003204.txt.gz | |
| PGS003205 (ExPRSweb_SleepApnea_finngen-R4-G6-SLEEPAPNO_PT_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 5,300 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003205/ScoringFiles/PGS003205.txt.gz | |
| PGS003206 (ExPRSweb_SleepApnea_finngen-R4-G6-SLEEPAPNO_PLINK_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 9,873 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003206/ScoringFiles/PGS003206.txt.gz | |
| PGS003207 (ExPRSweb_SleepApnea_finngen-R4-G6-SLEEPAPNO_DBSLMM_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 355 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003207/ScoringFiles/PGS003207.txt.gz | |
| PGS003208 (ExPRSweb_SleepApnea_finngen-R4-G6-SLEEPAPNO_PRSCS_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 12,076 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003208/ScoringFiles/PGS003208.txt.gz | |
| PGS003209 (ExPRSweb_SleepApnea_G6-SLEEPAPNO_LASSOSUM_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 328,671 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003209/ScoringFiles/PGS003209.txt.gz | |
| PGS003210 (ExPRSweb_SleepApnea_G6-SLEEPAPNO_PT_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 40,992 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003210/ScoringFiles/PGS003210.txt.gz | |
| PGS003211 (ExPRSweb_SleepApnea_G6-SLEEPAPNO_PLINK_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 39,223 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003211/ScoringFiles/PGS003211.txt.gz | |
| PGS003212 (ExPRSweb_SleepApnea_G6-SLEEPAPNO_DBSLMM_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 7,601,206 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003212/ScoringFiles/PGS003212.txt.gz | |
| PGS003213 (ExPRSweb_SleepApnea_G6-SLEEPAPNO_PRSCS_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 1,111,194 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003213/ScoringFiles/PGS003213.txt.gz | |
| PGS003214 (ExPRSweb_SleepApnea_finngen-R4-G6-SLEEPAPNO_LASSOSUM_UKB_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 5,812 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003214/ScoringFiles/PGS003214.txt.gz | |
| PGS003215 (ExPRSweb_SleepApnea_finngen-R4-G6-SLEEPAPNO_PT_UKB_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 1,209 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003215/ScoringFiles/PGS003215.txt.gz | |
| PGS003216 (ExPRSweb_SleepApnea_finngen-R4-G6-SLEEPAPNO_PLINK_UKB_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 688 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003216/ScoringFiles/PGS003216.txt.gz | |
| PGS003217 (ExPRSweb_SleepApnea_finngen-R4-G6-SLEEPAPNO_DBSLMM_UKB_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 46 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003217/ScoringFiles/PGS003217.txt.gz | |
| PGS003218 (ExPRSweb_SleepApnea_finngen-R4-G6-SLEEPAPNO_PRSCS_UKB_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Sleep apnea | sleep apnea | 12,097 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003218/ScoringFiles/PGS003218.txt.gz | |
| PGS003319 (ExPRSweb_Insomnia_1160_LASSOSUM_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Insomnia | insomnia | 578,551 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003319/ScoringFiles/PGS003319.txt.gz | |
| PGS003320 (ExPRSweb_Insomnia_1160_PT_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Insomnia | insomnia | 147 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003320/ScoringFiles/PGS003320.txt.gz | |
| PGS003321 (ExPRSweb_Insomnia_1160_PLINK_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Insomnia | insomnia | 148 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003321/ScoringFiles/PGS003321.txt.gz | |
| PGS003322 (ExPRSweb_Insomnia_1160_DBSLMM_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Insomnia | insomnia | 8,590,163 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003322/ScoringFiles/PGS003322.txt.gz | |
| PGS003323 (ExPRSweb_Insomnia_1160_PRSCS_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Insomnia | insomnia | 1,113,832 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003323/ScoringFiles/PGS003323.txt.gz | |
| PGS003324 (ExPRSweb_Insomnia_1200_LASSOSUM_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Insomnia | insomnia | 464,576 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003324/ScoringFiles/PGS003324.txt.gz | |
| PGS003325 (ExPRSweb_Insomnia_1200_PT_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Insomnia | insomnia | 28,289 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003325/ScoringFiles/PGS003325.txt.gz | |
| PGS003326 (ExPRSweb_Insomnia_1200_PLINK_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Insomnia | insomnia | 27,462 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003326/ScoringFiles/PGS003326.txt.gz | |
| PGS003327 (ExPRSweb_Insomnia_1200_DBSLMM_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Insomnia | insomnia | 6,214,923 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003327/ScoringFiles/PGS003327.txt.gz | |
| PGS003328 (ExPRSweb_Insomnia_1200_PRSCS_MGI_20211120) |
PGP000393 | Ma Y et al. Am J Hum Genet (2022) |
Insomnia | insomnia | 1,065,129 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003328/ScoringFiles/PGS003328.txt.gz | |
| PGS003333 (MDD-PRS) |
PGP000399 | Fang Y et al. Biol Psychiatry (2022) |
Major Depressive Disorder | major depressive disorder | 1,088,415 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003333/ScoringFiles/PGS003333.txt.gz |
| PGS003334 (PRS_dementia) |
PGP000402 | Chen Y et al. Arch Gerontol Geriatr (2022) |
Dementia | dementia | 27 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003334/ScoringFiles/PGS003334.txt.gz |
| PGS003414 (PRS47_RBD) |
PGP000427 | Krohn L et al. Nat Commun (2022) |
REM sleep behavior disorder | REM sleep behavior disorder | 47 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003414/ScoringFiles/PGS003414.txt.gz |
| PGS003440 (GRS11_nonapoeAD) |
PGP000444 | Petrican R et al. Sci Rep (2023) |
Alzheimer's disease in non APOE | APOE carrier status, Alzheimer disease |
11 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003440/ScoringFiles/PGS003440.txt.gz |
| PGS003441 (GRS28_AD) |
PGP000444 | Petrican R et al. Sci Rep (2023) |
Alzheimer's disease | Alzheimer disease | 28 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003441/ScoringFiles/PGS003441.txt.gz |
| PGS003442 (GRS8_MD) |
PGP000444 | Petrican R et al. Sci Rep (2023) |
Major depressive disorder | major depressive disorder | 8 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003442/ScoringFiles/PGS003442.txt.gz |
| PGS003479 (LDPred2_SleepApnea) |
PGP000456 | Zhang Y et al. EBioMedicine (2022) |
Obstructive sleep apnea | obstructive sleep apnea | 836,839 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003479/ScoringFiles/PGS003479.txt.gz |
| PGS003574 (GRS_Dementia21) |
PGP000459 | Mukadam N et al. PLoS One (2022) |
Alzheimer's disease (late onset) | Alzheimer disease | 21 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003574/ScoringFiles/PGS003574.txt.gz |
| PGS003576 (AutoImpAll.LifetimeMDD) |
PGP000461 | Dahl A et al. bioRxiv (2022) |Pre |
Major Depressive Disorder (Lifetime) | major depressive disorder | 5,776,312 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003576/ScoringFiles/PGS003576.txt.gz | |
| PGS003577 (AutoImpOnly.LifetimeMDD) |
PGP000461 | Dahl A et al. bioRxiv (2022) |Pre |
Major Depressive Disorder (Lifetime) | major depressive disorder | 5,776,312 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003577/ScoringFiles/PGS003577.txt.gz | |
| PGS003578 (MTAG.All.LifetimeMDD) |
PGP000461 | Dahl A et al. bioRxiv (2022) |Pre |
Major Depressive Disorder (Lifetime) | major depressive disorder | 4,786,322 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003578/ScoringFiles/PGS003578.txt.gz | |
| PGS003579 (MTAG.AllDep.LifetimeMDD) |
PGP000461 | Dahl A et al. bioRxiv (2022) |Pre |
Major Depressive Disorder (Lifetime) | major depressive disorder | 4,786,322 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003579/ScoringFiles/PGS003579.txt.gz | |
| PGS003580 (MTAG.AllDepEnvs.LifetimeMDD) |
PGP000461 | Dahl A et al. bioRxiv (2022) |Pre |
Major Depressive Disorder (Lifetime) | major depressive disorder | 4,786,322 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003580/ScoringFiles/PGS003580.txt.gz | |
| PGS003581 (MTAG.Envs.LifetimeMDD) |
PGP000461 | Dahl A et al. bioRxiv (2022) |Pre |
Major Depressive Disorder (Lifetime) | major depressive disorder | 4,861,398 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003581/ScoringFiles/PGS003581.txt.gz | |
| PGS003582 (MTAG.FamHist.LifetimeMDD) |
PGP000461 | Dahl A et al. bioRxiv (2022) |Pre |
Major Depressive Disorder (Lifetime) | major depressive disorder | 4,861,398 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003582/ScoringFiles/PGS003582.txt.gz | |
| PGS003583 (MTAG.GPpsy.LifetimeMDD) |
PGP000461 | Dahl A et al. bioRxiv (2022) |Pre |
Major Depressive Disorder (Lifetime) | major depressive disorder | 4,861,398 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003583/ScoringFiles/PGS003583.txt.gz | |
| PGS003584 (SoftImpAll.LifetimeMDD) |
PGP000461 | Dahl A et al. bioRxiv (2022) |Pre |
Major Depressive Disorder (Lifetime) | major depressive disorder | 5,776,312 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003584/ScoringFiles/PGS003584.txt.gz | |
| PGS003585 (SoftImpOnly.LifetimeMDD) |
PGP000461 | Dahl A et al. bioRxiv (2022) |Pre |
Major Depressive Disorder (Lifetime) | major depressive disorder | 5,776,312 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003585/ScoringFiles/PGS003585.txt.gz | |
| PGS003753 (PRS35445_ADHD) |
PGP000473 | Sato JR et al. Genes Brain Behav (2023) |
Attention deficit hyperactivity disorder | attention deficit hyperactivity disorder | 35,445 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003753/ScoringFiles/PGS003753.txt.gz |
| PGS003857 (GRS18_BMIunadj) |
PGP000496 | Sofer T et al. EBioMedicine (2023) |
Obstructive sleep apnea | obstructive sleep apnea | 18 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003857/ScoringFiles/PGS003857.txt.gz |
| PGS003858 (GRS6_BMIadj) |
PGP000496 | Sofer T et al. EBioMedicine (2023) |
Obstructive sleep apnea (BMI adjusted) | obstructive sleep apnea | 6 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003858/ScoringFiles/PGS003858.txt.gz |
| PGS003953 (AD_Bellenguez) |
PGP000503 | Sofer T et al. Alzheimers Res Ther (2023) |
Alzheimer's disease | Alzheimer disease | 1,937 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003953/ScoringFiles/PGS003953.txt.gz |
| PGS003954 (AD_FINNGEN) |
PGP000503 | Sofer T et al. Alzheimers Res Ther (2023) |
Alzheimer's disease | Alzheimer disease | 81 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003954/ScoringFiles/PGS003954.txt.gz |
| PGS003955 (AD_Jun) |
PGP000503 | Sofer T et al. Alzheimers Res Ther (2023) |
Alzheimer's disease | Alzheimer disease | 85 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003955/ScoringFiles/PGS003955.txt.gz |
| PGS003956 (AD_Kunkle_AFR) |
PGP000503 | Sofer T et al. Alzheimers Res Ther (2023) |
Alzheimer's disease | Alzheimer disease | 157 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003956/ScoringFiles/PGS003956.txt.gz |
| PGS003957 (AD_Kunkle) |
PGP000503 | Sofer T et al. Alzheimers Res Ther (2023) |
Alzheimer's disease | Alzheimer disease | 12,002 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003957/ScoringFiles/PGS003957.txt.gz |
| PGS003958 (AD_Unweighted_PRSsum) |
PGP000503 | Sofer T et al. Alzheimers Res Ther (2023) |
Alzheimer's disease | Alzheimer disease | 14,109 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003958/ScoringFiles/PGS003958.txt.gz |
| PGS003992 (dbslmm.auto.GCST90012877.AD) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Alzheimer's disease | Alzheimer disease | 1,136,212 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003992/ScoringFiles/PGS003992.txt.gz |
| PGS004008 (lassosum.auto.GCST90012877.AD) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Alzheimer's disease | Alzheimer disease | 5,663 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004008/ScoringFiles/PGS004008.txt.gz |
| PGS004034 (ldpred2.auto.GCST90012877.AD) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Alzheimer's disease | Alzheimer disease | 1,046,908 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004034/ScoringFiles/PGS004034.txt.gz |
| PGS004062 (megaprs.auto.GCST90012877.AD) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Alzheimer's disease | Alzheimer disease | 691,136 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004062/ScoringFiles/PGS004062.txt.gz |
| PGS004092 (prscs.auto.GCST90012877.AD) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Alzheimer's disease | Alzheimer disease | 1,109,233 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004092/ScoringFiles/PGS004092.txt.gz |
| PGS004116 (pt_clump.auto.GCST90012877.AD) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Alzheimer's disease | Alzheimer disease | 58 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004116/ScoringFiles/PGS004116.txt.gz |
| PGS004146 (sbayesr.auto.GCST90012877.AD) |
PGP000517 | Monti R et al. Am J Hum Genet (2024) |
Alzheimer's disease | Alzheimer disease | 915,771 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004146/ScoringFiles/PGS004146.txt.gz |
| PGS004227 (ad_apoe_gw_pgs) |
PGP000527 | Green RE et al. Alzheimers Res Ther (2023) |
Alzheimer's disease | Alzheimer disease | 15 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004227/ScoringFiles/PGS004227.txt.gz |
| PGS004228 (ad_apoe_0.1_pgs) |
PGP000527 | Green RE et al. Alzheimers Res Ther (2023) |
Alzheimer's disease | Alzheimer disease | 8,863 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004228/ScoringFiles/PGS004228.txt.gz |
| PGS004229 (ad_noapoe_0.1_pgs) |
PGP000527 | Green RE et al. Alzheimers Res Ther (2023) |
Alzheimer's disease | Alzheimer disease | 8,858 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004229/ScoringFiles/PGS004229.txt.gz |
| PGS004280 (GenoBoost_all-cause_dementia_0) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
All-cause dementia | dementia | 30 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004280/ScoringFiles/PGS004280.txt.gz |
| PGS004281 (GenoBoost_all-cause_dementia_1) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
All-cause dementia | dementia | 110 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004281/ScoringFiles/PGS004281.txt.gz |
| PGS004282 (GenoBoost_all-cause_dementia_2) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
All-cause dementia | dementia | 40 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004282/ScoringFiles/PGS004282.txt.gz |
| PGS004283 (GenoBoost_all-cause_dementia_3) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
All-cause dementia | dementia | 90 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004283/ScoringFiles/PGS004283.txt.gz |
| PGS004284 (GenoBoost_all-cause_dementia_4) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
All-cause dementia | dementia | 50 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004284/ScoringFiles/PGS004284.txt.gz |
| PGS004285 (GenoBoost_alzheimer_s_disease_0) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Alzheimer's disease | Alzheimer disease | 20 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004285/ScoringFiles/PGS004285.txt.gz |
| PGS004286 (GenoBoost_alzheimer_s_disease_1) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Alzheimer's disease | Alzheimer disease | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004286/ScoringFiles/PGS004286.txt.gz |
| PGS004287 (GenoBoost_alzheimer_s_disease_2) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Alzheimer's disease | Alzheimer disease | 30 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004287/ScoringFiles/PGS004287.txt.gz |
| PGS004288 (GenoBoost_alzheimer_s_disease_3) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Alzheimer's disease | Alzheimer disease | 200 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004288/ScoringFiles/PGS004288.txt.gz |
| PGS004289 (GenoBoost_alzheimer_s_disease_4) |
PGP000546 | Ohta R et al. Nat Commun (2024) |
Alzheimer's disease | Alzheimer disease | 40 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004289/ScoringFiles/PGS004289.txt.gz |
| PGS004318 (PRS29_dementia) |
PGP000548 | Feng J et al. BMC Geriatr (2023) |
Dementia | dementia | 29 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004318/ScoringFiles/PGS004318.txt.gz |
| PGS004449 (disease.F10.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
F10 (Mental and behavioural disorders due to use of alcohol) | alcohol-induced mental disorder | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004449/ScoringFiles/PGS004449.txt.gz |
| PGS004450 (disease.F17.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
F17 (Mental and behavioural disorders due to use of tobacco) | mental or behavioural disorder | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004450/ScoringFiles/PGS004450.txt.gz |
| PGS004451 (disease.F41.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
F41 (Other anxiety disorders) | anxiety disorder | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004451/ScoringFiles/PGS004451.txt.gz |
| PGS004452 (disease.G47.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
G47 (Sleep disorders) | Sleep Disorder | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004452/ScoringFiles/PGS004452.txt.gz |
| PGS004519 (meta.F10.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
F10 (Mental and behavioural disorders due to use of alcohol) | alcohol-induced mental disorder | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004519/ScoringFiles/PGS004519.txt.gz |
| PGS004520 (meta.F17.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
F17 (Mental and behavioural disorders due to use of tobacco) | mental or behavioural disorder | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004520/ScoringFiles/PGS004520.txt.gz |
| PGS004521 (meta.F41.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
F41 (Other anxiety disorders) | anxiety disorder | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004521/ScoringFiles/PGS004521.txt.gz |
| PGS004522 (meta.G47.score) |
PGP000561 | Jung H et al. Commun Biol (2024) |
G47 (Sleep disorders) | Sleep Disorder | 1,059,939 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004522/ScoringFiles/PGS004522.txt.gz |
| PGS004588 (PRS39_Eur) |
PGP000567 | Jung SH et al. JAMA Netw Open (2022) |
Alzheimer's disease | Alzheimer disease | 39 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004588/ScoringFiles/PGS004588.txt.gz | |
| PGS004589 (PRS80_trans) |
PGP000567 | Jung SH et al. JAMA Netw Open (2022) |
Alzheimer's disease | Alzheimer disease | 80 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004589/ScoringFiles/PGS004589.txt.gz | |
| PGS004590 (PRS363_rand_eff) |
PGP000569 | Lake J et al. Mol Psychiatry (2023) |
Alzheimer's disease | Alzheimer disease | 363 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004590/ScoringFiles/PGS004590.txt.gz |
| PGS004591 (PRS17_MDD) |
PGP000570 | Li D et al. BMC Med (2023) |
Major depressive disorder | major depressive disorder | 17 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004591/ScoringFiles/PGS004591.txt.gz |
| PGS004600 (PRS_AD83) |
PGP000578 | Tomassen J et al. BMC Neurol (2022) |
Alzheimer's disease | Alzheimer disease | 83 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004600/ScoringFiles/PGS004600.txt.gz |
| PGS004759 (depression_PRSmix_eur) |
PGP000604 | Truong B et al. Cell Genom (2024) |
Depression | major depressive disorder | 1,538,576 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004759/ScoringFiles/PGS004759.txt.gz |
| PGS004760 (depression_PRSmixPlus_eur) |
PGP000604 | Truong B et al. Cell Genom (2024) |
Depression | major depressive disorder | 2,141,267 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004760/ScoringFiles/PGS004760.txt.gz |
| PGS004863 (PRS74_AD) |
PGP000609 | Sleiman PM et al. Alzheimers Dement (2023) |
Alzheimer's disease | Alzheimer disease | 74 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004863/ScoringFiles/PGS004863.txt.gz |
| PGS004885 (INTERVENE_MegaPRS_MDD) |
PGP000618 | Jermy B et al. Nat Commun (2024) |
Major depressive disorder | major depressive disorder | 801,544 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004885/ScoringFiles/PGS004885.txt.gz | |
| PGS004898 (PRS_AD) |
PGP000624 | Vasiljevic E et al. Alzheimers Dement (2023) |
Alzheimer's disease | Alzheimer disease | 44 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004898/ScoringFiles/PGS004898.txt.gz |
| PGS004918 (PRS8_Synapse) |
PGP000649 | Lawingco T et al. Neurobiol Aging (2020) |
Late-onset Alzheimers disease (based on SNPs in genes involved in synaptic function) | late-onset Alzheimer's disease | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004918/ScoringFiles/PGS004918.txt.gz |
|
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|---|
| PPM000051 | PGS000025 (GRS) |
PSS000034| European Ancestry| 4,353 individuals |
PGP000015 | Chouraki V et al. J Alzheimers Dis (2016) |
Reported Trait: Incident Alzheimer's disease in APOE Ɛ4 carriers | HR: 1.24 [1.15, 1.34] | — | ΔC-index between models with and without GRS: 0.0112 [0.0015, 0.0208] | age at baseline, sex, education level | HRs are derived from a meta-analysis of studies (adjusted for study center, and participant relatedness) |
| PPM000052 | PGS000025 (GRS) |
PSS000035| European Ancestry| 15,334 individuals |
PGP000015 | Chouraki V et al. J Alzheimers Dis (2016) |
Reported Trait: Incident Alzheimer's disease in APOE Ɛ4 non-carriers | HR: 1.13 [1.08, 1.18] | — | ΔC-index between models with and without GRS: 0.0018 [-0.0003, 0.0039] | age at baseline, sex, education level | HRs are derived from a meta-analysis of studies (adjusted for study center, and participant relatedness) |
| PPM000050 | PGS000025 (GRS) |
PSS000033| European Ancestry| 19,687 individuals |
PGP000015 | Chouraki V et al. J Alzheimers Dis (2016) |
Reported Trait: Incident Alzheimer's disease | HR: 1.17 [1.13, 1.21] | — | ΔC-index between models with and without GRS: 0.0043 [0.0019, 0.0067] | age at baseline, sex, education level, APOE Ɛ4 status | HRs are derived from a meta-analysis of studies (adjusted for study center, and participant relatedness) |
| PPM000053 | PGS000026 (PHS) |
PSS000036| European Ancestry| 17,956 individuals |
PGP000016 | Desikan RS et al. PLoS Med (2017) |
Reported Trait: Alzheimer disease | — | — | r (correlation between between binned quantiles of PHS-predicted and empirical age of AD onset): 0.9 | APOE risk alleles (e2 and e4), age, sex, genetic PCs 1-5 | — |
| PPM002504 | PGS000026 (PHS) |
PSS001127| European Ancestry| 8,415 individuals |
PGP000222 | Leonenko G et al. Ann Clin Transl Neurol (2019) |Ext. |
Reported Trait: Age at Alzheimer's disease onset | β: 0.11 (0.02) | — | — | Gender, PCs (1-3), APOE(ε2 + ε4) | Due to SNP availability issues in the dataset, only 25 out of the 31 variants in Desikan et al's polygenic hazard score (PGS000026) were used. No APOE alleles were included |
| PPM014811 | PGS000026 (PHS) |
PSS009898| Ancestry Not Reported| 780 individuals |
PGP000340 | Vacher M et al. BMC Genomics (2022) |Ext. |
Reported Trait: Aβ-amyloid deposition in neocortical region | β: 19.98 [14.3, 25.7] | — | — | — | — |
| PPM014812 | PGS000026 (PHS) |
PSS009898| Ancestry Not Reported| 780 individuals |
PGP000340 | Vacher M et al. BMC Genomics (2022) |Ext. |
Reported Trait: Aβ-amyloid deposition in posterior cingulate region | β: 25.54 [18.4, 32.6] | — | — | — | — |
| PPM014814 | PGS000026 (PHS) |
PSS009900| Ancestry Not Reported| 278 individuals |
PGP000340 | Vacher M et al. BMC Genomics (2022) |Ext. |
Reported Trait: Aβ-amyloid deposition in neocortical region (in APOE E4 carriers) | β: 25.28 [17.4, 33.2] | — | — | — | — |
| PPM014815 | PGS000026 (PHS) |
PSS009900| Ancestry Not Reported| 278 individuals |
PGP000340 | Vacher M et al. BMC Genomics (2022) |Ext. |
Reported Trait: Aβ-amyloid deposition in posterior cingulate region (in APOE E4 carriers) | β: 33.06 [23.3, 42.8] | — | — | — | — |
| PPM014816 | PGS000026 (PHS) |
PSS009900| Ancestry Not Reported| 278 individuals |
PGP000340 | Vacher M et al. BMC Genomics (2022) |Ext. |
Reported Trait: Aβ-amyloid deposition in frontal cortex region (in APOE E4 carriers) | β: 26.63 [18.0, 35.3] | — | — | — | — |
| PPM014817 | PGS000026 (PHS) |
PSS009899| Ancestry Not Reported| 502 individuals |
PGP000340 | Vacher M et al. BMC Genomics (2022) |Ext. |
Reported Trait: Aβ-amyloid deposition in neocortical region (in APOE E4 non-carriers) | β: 12.61 [3.9, 21.3] | — | — | — | — |
| PPM014818 | PGS000026 (PHS) |
PSS009899| Ancestry Not Reported| 502 individuals |
PGP000340 | Vacher M et al. BMC Genomics (2022) |Ext. |
Reported Trait: Aβ-amyloid deposition in posterior cingulate region (in APOE E4 non-carriers) | β: 14.28 [3.42, 25.1] | — | — | — | — |
| PPM014819 | PGS000026 (PHS) |
PSS009899| Ancestry Not Reported| 502 individuals |
PGP000340 | Vacher M et al. BMC Genomics (2022) |Ext. |
Reported Trait: Aβ-amyloid deposition in frontal cortex region (in APOE E4 non-carriers) | β: 13.62 [4.24, 23.0] | — | — | — | — |
| PPM014813 | PGS000026 (PHS) |
PSS009898| Ancestry Not Reported| 780 individuals |
PGP000340 | Vacher M et al. BMC Genomics (2022) |Ext. |
Reported Trait: Aβ-amyloid deposition in frontal cortex region | β: 21.19 [15.0, 27.4] | — | — | — | — |
| PPM000137 | PGS000053 (ALZ21_NIA-LOAD) |
PSS000085| European Ancestry| 4,792 individuals |
PGP000039 | Tosto G et al. Neurology (2017) |
Reported Trait: Alzheimer's disease (age-at-onset) | β: -0.7 (0.15) years | — | — | — | — |
| PPM000133 | PGS000053 (ALZ21_NIA-LOAD) |
PSS000085| European Ancestry| 4,792 individuals |
PGP000039 | Tosto G et al. Neurology (2017) |
Reported Trait: Familial late-onset Alzheimer's disease (LOAD) | OR: 1.29 [1.21, 1.37] | — | — | Age, sex | — |
| PPM000134 | PGS000053 (ALZ21_NIA-LOAD) |
PSS000085| European Ancestry| 4,792 individuals |
PGP000039 | Tosto G et al. Neurology (2017) |
Reported Trait: Familial late-onset Alzheimer's disease (LOAD) | OR: 1.29 [1.21, 1.38] | — | — | Age, sex, APOE e4 | — |
| PPM000138 | PGS000054 (ALZ21_EFIGA) |
PSS000084| Hispanic or Latin American Ancestry| 3,324 individuals |
PGP000039 | Tosto G et al. Neurology (2017) |
Reported Trait: Alzheimer's disease (age-at-onset) | β: -0.86 (0.15) years | — | — | — | — |
| PPM000135 | PGS000054 (ALZ21_EFIGA) |
PSS000084| Hispanic or Latin American Ancestry| 3,324 individuals |
PGP000039 | Tosto G et al. Neurology (2017) |
Reported Trait: Familial late-onset Alzheimer's disease (LOAD) | OR: 1.73 [1.57, 1.93] | — | — | Age, sex | — |
| PPM000136 | PGS000054 (ALZ21_EFIGA) |
PSS000084| Hispanic or Latin American Ancestry| 3,324 individuals |
PGP000039 | Tosto G et al. Neurology (2017) |
Reported Trait: Familial late-onset Alzheimer's disease (LOAD) | OR: 1.71 [1.55, 1.9] | — | — | Age, sex, APOE e4 | — |
| PPM000417 | PGS000133 (SCZ_BVU) |
PSS000238| European Ancestry| 33,694 individuals |
PGP000065 | Zheutlin AB et al. Am J Psychiatry (2019) |
Reported Trait: Psychosis | OR: 1.3755 | — | — | age, sex, 10 PCs of ancestry, genotyping platform, genotyping batch | *SNP weights were adjusted for use in this cohort |
| PPM000413 | PGS000133 (SCZ_BVU) |
PSS000237| European Ancestry| 33,694 individuals |
PGP000065 | Zheutlin AB et al. Am J Psychiatry (2019) |
Reported Trait: Schizophrenia | OR: 1.691 | AUROC: 0.6 [0.55, 0.66] | — | age, sex, 10 PCs of ancestry, genotyping platform, genotyping batch | *SNP weights were adjusted for use in this cohort |
| PPM000418 | PGS000134 (SCZ_GHS) |
PSS000240| European Ancestry| 44,436 individuals |
PGP000065 | Zheutlin AB et al. Am J Psychiatry (2019) |
Reported Trait: Psychosis | OR: 1.2224 | — | — | age, sex, 10 PCs of ancestry, genotyping platform, genotyping batch | *SNP weights were adjusted for use in this cohort |
| PPM000414 | PGS000134 (SCZ_GHS) |
PSS000239| European Ancestry| 44,436 individuals |
PGP000065 | Zheutlin AB et al. Am J Psychiatry (2019) |
Reported Trait: Schizophrenia | OR: 1.483 | AUROC: 0.6 [0.56, 0.64] | — | age, sex, 10 PCs of ancestry, genotyping platform, genotyping batch | *SNP weights were adjusted for use in this cohort |
| PPM000415 | PGS000135 (SCZ_MTS) |
PSS000241| European Ancestry| 9,569 individuals |
PGP000065 | Zheutlin AB et al. Am J Psychiatry (2019) |
Reported Trait: Schizophrenia | — | AUROC: 0.74 [0.67, 0.81] | — | age, sex, 10 PCs of ancestry, genotyping platform, genotyping batch | *SNP weights were adjusted for use in this cohort |
| PPM000420 | PGS000136 (SCZ_PBK) |
PSS000244| European Ancestry| 18,461 individuals |
PGP000065 | Zheutlin AB et al. Am J Psychiatry (2019) |
Reported Trait: Psychosis | OR: 1.4768 | — | — | age, sex, 10 PCs of ancestry, genotyping platform, genotyping batch | *SNP weights were adjusted for use in this cohort |
| PPM000416 | PGS000136 (SCZ_PBK) |
PSS000243| European Ancestry| 18,461 individuals |
PGP000065 | Zheutlin AB et al. Am J Psychiatry (2019) |
Reported Trait: Schizophrenia | OR: 1.7 | AUROC: 0.64 [0.6, 0.69] | — | age, sex, 10 PCs of ancestry, genotyping platform, genotyping batch | *SNP weights were adjusted for use in this cohort |
| PPM000430 | PGS000138 (LifetimeMDD) |
PSS000250| European Ancestry| 36,709 individuals |
PGP000068 | Cai N et al. Nat Genet (2020) |
Reported Trait: Major Depressive Disorder status | — | AUROC: 0.5611 | R²: 0.01817 | Cohort | — |
| PPM000431 | PGS000139 (MDDRecur) |
PSS000250| European Ancestry| 36,709 individuals |
PGP000068 | Cai N et al. Nat Genet (2020) |
Reported Trait: Major Depressive Disorder status | — | AUROC: 0.54874 | R²: 0.01097 | Cohort | — |
| PPM000432 | PGS000140 (GPpsy) |
PSS000250| European Ancestry| 36,709 individuals |
PGP000068 | Cai N et al. Nat Genet (2020) |
Reported Trait: Major Depressive Disorder status | — | AUROC: 0.53193 | R²: 0.00481 | Cohort | — |
| PPM000433 | PGS000141 (Psypsy) |
PSS000250| European Ancestry| 36,709 individuals |
PGP000068 | Cai N et al. Nat Genet (2020) |
Reported Trait: Major Depressive Disorder status | — | AUROC: 0.52988 | R²: 0.00438 | Cohort | — |
| PPM000434 | PGS000142 (DepAll) |
PSS000250| European Ancestry| 36,709 individuals |
PGP000068 | Cai N et al. Nat Genet (2020) |
Reported Trait: Major Depressive Disorder status | — | AUROC: 0.5333 | R²: 0.00492 | Cohort | — |
| PPM000437 | PGS000145 (ICD10Dep) |
PSS000250| European Ancestry| 36,709 individuals |
PGP000068 | Cai N et al. Nat Genet (2020) |
Reported Trait: Major Depressive Disorder status | — | AUROC: 0.5251 | R²: 0.0032 | Cohort | — |
| PPM000564 | PGS000193 (MDD_0.001_Coleman_2020) |
PSS000294| European Ancestry| 92,957 individuals |
PGS000080 | Coleman JRI et al. Mol Psychiatry (2020) |
Reported Trait: Major depressive disorder | OR: 1.179 | — | R²: 0.01485 Nagelkerke pseudo-R2 (increase when adding PRS to null model of covariates): 0.00785 |
batch, centre, genomic prinicipal components (x6) | — |
| PPM000879 | PGS000327 (ASD2019) |
PSS000435| European Ancestry| 7,148 individuals |
PGP000098 | Grove J et al. Nat Genet (2019) |
Reported Trait: Autism spectrum disorder | OR: 1.33 [1.3, 1.36] | — | R²: 0.0245 | Genetic PCs, genotyping wave | *Pooled cross-validation performance on 1/5th of iPSYCH sample. PRS is based on full iPSYCH+PGC GWAS |
| PPM000901 | PGS000334 (GRSfull_22) |
PSS000449| European Ancestry| 3,810 individuals |
PGP000101 | Zhang Q et al. Nat Commun (2020) |
Reported Trait: Late-onset Alzheimer’s disease | — | — | R²: 0.191 [0.131, 0.269] | — | R2 = variance explained on the liability scale |
| PPM001925 | PGS000756 (GRS3_Nar) |
PSS000966| East Asian Ancestry| 2,884 individuals |
PGP000162 | Ouyang H et al. Ann Transl Med (2020) |
Reported Trait: Incident narcolepsy | OR: 1.149 [1.119, 1.181] | — | Odds Ratio (OR, high vs low risk): 2.586 [2.109, 3.173] | — | Individuals with a high polygenic risk had a score ≥28. Individuals with a low polygenic risk had a score <25. |
| PPM001926 | PGS000756 (GRS3_Nar) |
PSS000966| East Asian Ancestry| 2,884 individuals |
PGP000162 | Ouyang H et al. Ann Transl Med (2020) |
Reported Trait: Incident narcolepsy | OR: 1.152 [1.12, 1.185] | AUROC: 0.723 | Odds Ratio (OR, high vs low risk): 2.602 [2.097, 3.232] | Gender | Individuals with a high polygenic risk had a score ≥28. Individuals with a low polygenic risk had a score <25. |
| PPM001927 | PGS000757 (GRS4_Nar) |
PSS000966| East Asian Ancestry| 2,884 individuals |
PGP000162 | Ouyang H et al. Ann Transl Med (2020) |
Reported Trait: Incident narcolepsy | OR: 1.449 [1.367, 1.536] | — | Odds Ratio (OR, high vs low risk): 4.298 [3.378, 5.481] | — | Individuals with a high polygenic risk had a score ≥8. Individuals with a low polygenic risk had a score <6. |
| PPM001928 | PGS000757 (GRS4_Nar) |
PSS000966| East Asian Ancestry| 2,884 individuals |
PGP000162 | Ouyang H et al. Ann Transl Med (2020) |
Reported Trait: Incident narcolepsy | OR: 1.442 [1.357, 1.534] | AUROC: 0.736 | Odds Ratio (OR, high vs low risk): 4.157 [3.224, 5.371] | Gender | Individuals with a high polygenic risk had a score ≥8. Individuals with a low polygenic risk had a score <6. |
| PPM001972 | PGS000767 (GRS14) |
PSS000984| Multi-ancestry (including European)| 62 individuals |
PGP000174 | Guffanti G et al. Transl Psychiatry (2019) |
Reported Trait: Bilateral Nucleus acumbens stress induced reward prediciton error change | — | — | R²: 0.065 | PCs(1-2) | — |
| PPM001973 | PGS000767 (GRS14) |
PSS000985| Multi-ancestry (including European)| 63 individuals |
PGP000174 | Guffanti G et al. Transl Psychiatry (2019) |
Reported Trait: Bilateral putamen stress induced reward prediciton error change | — | — | R²: 0.074 | PCs(1-2) | — |
| PPM001974 | PGS000767 (GRS14) |
PSS000986| Multi-ancestry (including European)| 73 individuals |
PGP000174 | Guffanti G et al. Transl Psychiatry (2019) |
Reported Trait: Bilateral nucleus acumbens volume | — | — | R²: 0.064 | PCs(1-2) | — |
| PPM001975 | PGS000767 (GRS14) |
PSS000986| Multi-ancestry (including European)| 73 individuals |
PGP000174 | Guffanti G et al. Transl Psychiatry (2019) |
Reported Trait: Bilateral putamen volume | — | — | R²: 0.095 | PCs(1-2) | — |
| PPM002022 | PGS000779 (PGS7_AD) |
PSS001005| East Asian Ancestry| 112 individuals |
PGP000183 | Zhou X et al. Alzheimers Dement (Amst) (2020) |
Reported Trait: Alzheimer's disease | — | AUROC: 0.612 | Beta (β, top 33.3% vs bottom 33.3%): 1.485 (0.602) | Age, sex | — |
| PPM002023 | PGS000779 (PGS7_AD) |
PSS001006| European Ancestry| 2,696 individuals |
PGP000183 | Zhou X et al. Alzheimers Dement (Amst) (2020) |
Reported Trait: Alzheimer's disease | — | AUROC: 0.717 | Beta (β, top 33.3% vs bottom 33.3%): 2.283 (1.021) | Age, sex, PCs(1-5) | — |
| PPM002140 | PGS000811 (AD-PRS_39) |
PSS001052| European Ancestry| 2,052 individuals |
PGP000196 | Najar J et al. Alzheimers Dement (Amst) (2021) |
Reported Trait: Incident dementia in APOE ɛ4 non-carriers | HR: 1.22 [1.1, 1.35] | — | — | Age at blood sampling, birth year, sex, PCs(1-10) | — |
| PPM002143 | PGS000811 (AD-PRS_39) |
PSS001052| European Ancestry| 2,052 individuals |
PGP000196 | Najar J et al. Alzheimers Dement (Amst) (2021) |
Reported Trait: Incident dementia in APOE ɛ4 non-carriers aged between 70 and 94 | HR: 1.16 [1.01, 1.34] | — | — | Age at blood sampling, birth year, sex, PCs(1-10) | — |
| PPM002144 | PGS000811 (AD-PRS_39) |
PSS001052| European Ancestry| 2,052 individuals |
PGP000196 | Najar J et al. Alzheimers Dement (Amst) (2021) |
Reported Trait: Incident dementia in APOE ɛ4 non-carriers aged 95 years or above | HR: 1.28 [1.1, 1.5] | — | — | Age at blood sampling, birth year, sex, PCs(1-10) | — |
| PPM002145 | PGS000811 (AD-PRS_39) |
PSS001052| European Ancestry| 2,052 individuals |
PGP000196 | Najar J et al. Alzheimers Dement (Amst) (2021) |
Reported Trait: Incident dementia in APOE ɛ4 carriers aged 95 years or above | HR: 0.62 [0.41, 0.95] | — | — | Age at blood sampling, birth year, sex, PCs(1-10) | — |
| PPM002141 | PGS000812 (AD-PRS_57) |
PSS001052| European Ancestry| 2,052 individuals |
PGP000196 | Najar J et al. Alzheimers Dement (Amst) (2021) |
Reported Trait: Incident dementia | HR: 1.09 [1.01, 1.19] | — | — | Age at blood sampling, birth year, sex, PCs(1-10) | — |
| PPM002142 | PGS000812 (AD-PRS_57) |
PSS001052| European Ancestry| 2,052 individuals |
PGP000196 | Najar J et al. Alzheimers Dement (Amst) (2021) |
Reported Trait: Incident dementia in APOE ɛ4 non-carriers | HR: 1.15 [1.05, 1.27] | — | — | Age at blood sampling, birth year, sex, PCs(1-10) | — |
| PPM002146 | PGS000812 (AD-PRS_57) |
PSS001052| European Ancestry| 2,052 individuals |
PGP000196 | Najar J et al. Alzheimers Dement (Amst) (2021) |
Reported Trait: Incident dementia in individuals aged 95 or above | HR: 1.15 [1.01, 1.32] | — | — | Age at blood sampling, birth year, sex, PCs(1-10) | — |
| PPM002216 | PGS000823 (GRS23_AD) |
PSS001080| European Ancestry| 12,255 individuals |
PGP000207 | van der Lee SJ et al. Lancet Neurol (2018) |
Reported Trait: Incident dementia at age 85 in individuals homozygous for APOE ε4 | — | — | Cumulative risk p-value (top 33.3% vs bottom 33.3%): 0.00022 | Mortality | — |
| PPM002218 | PGS000823 (GRS23_AD) |
PSS001080| European Ancestry| 12,255 individuals |
PGP000207 | van der Lee SJ et al. Lancet Neurol (2018) |
Reported Trait: Incident dementia at age 90 | — | — | Cumulative risk p-value (top 33.3% vs bottom 33.3%): 5.20e-13 | Mortality | — |
| PPM002219 | PGS000823 (GRS23_AD) |
PSS001081| European Ancestry| 12,978 individuals |
PGP000208 | Riaz M et al. Aging Cell (2021) |Ext. |
Reported Trait: Incident all-cause dementia | — | — | Hazard Ratio (HR, top 33.3% vs bottom 33.3%): 1.36 [1.04, 1.76] | Age at enrolment, sex | — |
| PPM002220 | PGS000823 (GRS23_AD) |
PSS001081| European Ancestry| 12,978 individuals |
PGP000208 | Riaz M et al. Aging Cell (2021) |Ext. |
Reported Trait: Incident all-cause dementia | — | — | Hazard Ratio (HR, top 33.3% vs bottom 33.3%): 1.36 [1.04, 1.77] | Age at enrolment, sex, competing risk of death | — |
| PPM002215 | PGS000823 (GRS23_AD) |
PSS001080| European Ancestry| 12,255 individuals |
PGP000207 | van der Lee SJ et al. Lancet Neurol (2018) |
Reported Trait: Incident Alzheimer's disease at age 80 in individuals homozygous for APOE ε4 | — | — | Cumulative risk p-value (top 33.3% vs bottom 33.3%): 0.0056 | Non-Alzheimer's disease dementia, mortality | — |
| PPM002217 | PGS000823 (GRS23_AD) |
PSS001080| European Ancestry| 12,255 individuals |
PGP000207 | van der Lee SJ et al. Lancet Neurol (2018) |
Reported Trait: Incident Alzheimer's disease at age 85 | — | — | Cumulative risk p-value (top 33.3% vs bottom 33.3%): 7.90e-14 | Non-Alzheimer's disease dementia, mortality | — |
| PPM002214 | PGS000823 (GRS23_AD) |
PSS001080| European Ancestry| 12,255 individuals |
PGP000207 | van der Lee SJ et al. Lancet Neurol (2018) |
Reported Trait: Incident Alzheimer's disease at age 85 in individuals homozygous for APOE ε4 | — | — | Cumulative risk p-value (top 33.3% vs bottom 33.3%): 0.0085 | Non-Alzheimer's disease dementia, mortality | — |
| PPM002505 | PGS000876 (PRS31_AD) |
PSS001127| European Ancestry| 8,415 individuals |
PGP000222 | Leonenko G et al. Ann Clin Transl Neurol (2019) |
Reported Trait: Age at Alzheimer's disease onset | β: 0.13 (0.02) | — | — | Gender, PCs (1-3), APOE(ε2 + ε4) | Due to SNP availability issues in the dataset, only 25 out of the 31 variants used to construct the polygenic risk score were used. |
| PPM002506 | PGS000876 (PRS31_AD) |
PSS001125| European Ancestry| 9,903 individuals |
PGP000222 | Leonenko G et al. Ann Clin Transl Neurol (2019) |
Reported Trait: Age at Alzheimer's disease onset | β: 0.28 (0.04) | — | — | Gender, PCs (1-3), APOE ε2, APOE ε4 | — |
| PPM002507 | PGS000876 (PRS31_AD) |
PSS001126| European Ancestry| 4,100 individuals |
PGP000222 | Leonenko G et al. Ann Clin Transl Neurol (2019) |
Reported Trait: Age at Alzheimer's disease onset in individuals above the age of 55 | β: 0.29 (0.03) | — | — | Gender, PCs (1-3), APOE ε2, APOE ε4 | — |
| PPM002634 | PGS000898 (PRS39_AD) |
PSS001167| European Ancestry| 2,394 individuals |
PGP000231 | de Rojas I et al. Nat Commun (2021) |
Reported Trait: Alzheimer's disease (clinically confirmed) | OR: 1.3 [1.18, 1.44] | — | — | PCs(1-4) | — |
| PPM002635 | PGS000898 (PRS39_AD) |
PSS001167| European Ancestry| 2,394 individuals |
PGP000231 | de Rojas I et al. Nat Commun (2021) |
Reported Trait: Alzheimer's disease (pathologically confirmed) | OR: 1.38 [1.21, 1.58] | — | — | PCs(1-4) | — |
| PPM002636 | PGS000898 (PRS39_AD) |
PSS001167| European Ancestry| 2,394 individuals |
PGP000231 | de Rojas I et al. Nat Commun (2021) |
Reported Trait: Alzheimer's disease (pathologically confirmed, males) | OR: 1.33 [1.13, 1.56] | — | — | PCs(1-4) | — |
| PPM002637 | PGS000898 (PRS39_AD) |
PSS001167| European Ancestry| 2,394 individuals |
PGP000231 | de Rojas I et al. Nat Commun (2021) |
Reported Trait: Alzheimer's disease (pathologically confirmed, females) | OR: 1.32 [1.19, 1.47] | — | — | PCs(1-4) | — |
| PPM002638 | PGS000898 (PRS39_AD) |
PSS001167| European Ancestry| 2,394 individuals |
PGP000231 | de Rojas I et al. Nat Commun (2021) |
Reported Trait: Early-onset Alzheimer's disease (< 65 years) | OR: 1.58 [1.22, 2.05] | — | — | PCs(1-4) | — |
| PPM002639 | PGS000898 (PRS39_AD) |
PSS001167| European Ancestry| 2,394 individuals |
PGP000231 | de Rojas I et al. Nat Commun (2021) |
Reported Trait: Late-onset Alzheimer's disease (> 85 years) | OR: 1.29 [1.1, 1.51] | — | — | PCs(1-4) | — |
| PPM002681 | PGS000907 (PRS_MDD) |
PSS001279| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Escitalopram takers | OR: 1.0 [0.92, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002682 | PGS000907 (PRS_MDD) |
PSS001284| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Venlafaxine takers | OR: 1.05 [0.96, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002684 | PGS000907 (PRS_MDD) |
PSS001281| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Mirtazapine takers | OR: 1.05 [0.91, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002685 | PGS000907 (PRS_MDD) |
PSS001277| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Desvenlafaxine takers | OR: 1.01 [0.91, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002686 | PGS000907 (PRS_MDD) |
PSS001276| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Citalopram takers | OR: 1.02 [0.9, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002687 | PGS000907 (PRS_MDD) |
PSS001280| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Fluoxetine takers | OR: 1.06 [0.96, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002688 | PGS000907 (PRS_MDD) |
PSS001278| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Duloxetine takers | OR: 1.06 [0.95, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002689 | PGS000907 (PRS_MDD) |
PSS001282| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Paroxetine takers | OR: 1.08 [0.92, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.11 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002690 | PGS000907 (PRS_MDD) |
PSS001243| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Sertraline takers | OR: 1.06 [0.98, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002691 | PGS000907 (PRS_MDD) |
PSS001239| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Escitalopram takers | OR: 1.06 [0.98, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002692 | PGS000907 (PRS_MDD) |
PSS001244| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Venlafaxine takers | OR: 1.01 [0.93, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002693 | PGS000907 (PRS_MDD) |
PSS001235| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Amitriptyline takers | OR: 0.96 [0.83, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002694 | PGS000907 (PRS_MDD) |
PSS001241| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Mirtazapine takers | OR: 1.07 [0.93, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002695 | PGS000907 (PRS_MDD) |
PSS001237| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Desvenlafaxine takers | OR: 0.97 [0.87, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002696 | PGS000907 (PRS_MDD) |
PSS001236| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Citalopram takers | OR: 0.99 [0.87, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002697 | PGS000907 (PRS_MDD) |
PSS001240| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Fluoxetine takers | OR: 1.16 [1.04, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.41 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002698 | PGS000907 (PRS_MDD) |
PSS001238| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Duloxetine takers | OR: 0.98 [0.88, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002699 | PGS000907 (PRS_MDD) |
PSS001242| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dizziness in Paroxetine takers | OR: 1.08 [0.93, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.12 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002700 | PGS000907 (PRS_MDD) |
PSS001373| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Sertraline takers | OR: 1.03 [0.94, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002701 | PGS000907 (PRS_MDD) |
PSS001369| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Escitalopram takers | OR: 1.01 [0.9, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002702 | PGS000907 (PRS_MDD) |
PSS001374| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Venlafaxine takers | OR: 1.1 [1.0, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.18 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002703 | PGS000907 (PRS_MDD) |
PSS001365| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Amitriptyline takers | OR: 0.99 [0.81, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002704 | PGS000907 (PRS_MDD) |
PSS001371| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Mirtazapine takers | OR: 1.03 [0.86, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002705 | PGS000907 (PRS_MDD) |
PSS001367| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Desvenlafaxine takers | OR: 1.04 [0.92, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002707 | PGS000907 (PRS_MDD) |
PSS001370| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Fluoxetine takers | OR: 1.06 [0.95, 1.19] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002708 | PGS000907 (PRS_MDD) |
PSS001368| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Duloxetine takers | OR: 0.9 [0.79, 1.04] | — | Variance explained (Nagelkerke's R2*100): 0.21 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002709 | PGS000907 (PRS_MDD) |
PSS001372| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Paroxetine takers | OR: 1.19 [1.0, 1.41] | — | Variance explained (Nagelkerke's R2*100): 0.53 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002710 | PGS000907 (PRS_MDD) |
PSS001303| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Sertraline takers | OR: 1.13 [0.97, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.18 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002711 | PGS000907 (PRS_MDD) |
PSS001299| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Escitalopram takers | OR: 0.96 [0.8, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002712 | PGS000907 (PRS_MDD) |
PSS001304| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Venlafaxine takers | OR: 1.22 [1.03, 1.45] | — | Variance explained (Nagelkerke's R2*100): 0.51 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002713 | PGS000907 (PRS_MDD) |
PSS001295| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Amitriptyline takers | OR: 1.06 [0.8, 1.4] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002715 | PGS000907 (PRS_MDD) |
PSS001297| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Desvenlafaxine takers | OR: 1.0 [0.8, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002716 | PGS000907 (PRS_MDD) |
PSS001296| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Citalopram takers | OR: 0.95 [0.72, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002717 | PGS000907 (PRS_MDD) |
PSS001300| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Fluoxetine takers | OR: 1.3 [1.05, 1.6] | — | Variance explained (Nagelkerke's R2*100): 0.77 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002718 | PGS000907 (PRS_MDD) |
PSS001298| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Duloxetine takers | OR: 0.99 [0.82, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002720 | PGS000907 (PRS_MDD) |
PSS001263| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Sertraline takers | OR: 1.04 [0.98, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002721 | PGS000907 (PRS_MDD) |
PSS001259| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Escitalopram takers | OR: 1.01 [0.94, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002722 | PGS000907 (PRS_MDD) |
PSS001264| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Venlafaxine takers | OR: 0.98 [0.91, 1.05] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002723 | PGS000907 (PRS_MDD) |
PSS001255| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Amitriptyline takers | OR: 1.06 [0.95, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002724 | PGS000907 (PRS_MDD) |
PSS001261| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Mirtazapine takers | OR: 1.05 [0.94, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002725 | PGS000907 (PRS_MDD) |
PSS001257| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Desvenlafaxine takers | OR: 1.09 [0.99, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.2 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002726 | PGS000907 (PRS_MDD) |
PSS001256| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Citalopram takers | OR: 1.11 [1.0, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.23 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002727 | PGS000907 (PRS_MDD) |
PSS001260| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Fluoxetine takers | OR: 1.0 [0.92, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002728 | PGS000907 (PRS_MDD) |
PSS001258| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Duloxetine takers | OR: 1.03 [0.93, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002729 | PGS000907 (PRS_MDD) |
PSS001262| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Dry mouth in Paroxetine takers | OR: 0.98 [0.86, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002730 | PGS000907 (PRS_MDD) |
PSS001403| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Sertraline takers | OR: 0.99 [0.92, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002731 | PGS000907 (PRS_MDD) |
PSS001399| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Escitalopram takers | OR: 0.97 [0.89, 1.06] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002732 | PGS000907 (PRS_MDD) |
PSS001404| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Venlafaxine takers | OR: 1.04 [0.96, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002733 | PGS000907 (PRS_MDD) |
PSS001395| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Amitriptyline takers | OR: 1.14 [0.96, 1.37] | — | Variance explained (Nagelkerke's R2*100): 0.3 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002734 | PGS000907 (PRS_MDD) |
PSS001401| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Mirtazapine takers | OR: 1.05 [0.9, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002735 | PGS000907 (PRS_MDD) |
PSS001397| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Desvenlafaxine takers | OR: 0.99 [0.9, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002736 | PGS000907 (PRS_MDD) |
PSS001396| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Citalopram takers | OR: 1.14 [0.99, 1.3] | — | Variance explained (Nagelkerke's R2*100): 0.29 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002737 | PGS000907 (PRS_MDD) |
PSS001400| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Fluoxetine takers | OR: 1.04 [0.94, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002738 | PGS000907 (PRS_MDD) |
PSS001398| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Duloxetine takers | OR: 0.96 [0.86, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002739 | PGS000907 (PRS_MDD) |
PSS001402| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Sweating in Paroxetine takers | OR: 1.1 [0.94, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.17 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002741 | PGS000907 (PRS_MDD) |
PSS001309| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Escitalopram takers | OR: 1.06 [0.98, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002742 | PGS000907 (PRS_MDD) |
PSS001314| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Venlafaxine takers | OR: 1.08 [1.0, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002743 | PGS000907 (PRS_MDD) |
PSS001305| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Amitriptyline takers | OR: 1.12 [0.95, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.22 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002744 | PGS000907 (PRS_MDD) |
PSS001311| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Mirtazapine takers | OR: 1.08 [0.93, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002745 | PGS000907 (PRS_MDD) |
PSS001307| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Desvenlafaxine takers | OR: 1.06 [0.96, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002746 | PGS000907 (PRS_MDD) |
PSS001306| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Citalopram takers | OR: 1.11 [0.99, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.24 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002747 | PGS000907 (PRS_MDD) |
PSS001310| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Fluoxetine takers | OR: 1.06 [0.97, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002748 | PGS000907 (PRS_MDD) |
PSS001308| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Duloxetine takers | OR: 1.16 [1.04, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.55 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002749 | PGS000907 (PRS_MDD) |
PSS001312| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Paroxetine takers | OR: 1.1 [0.96, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.21 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002750 | PGS000907 (PRS_MDD) |
PSS001423| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Sertraline takers | OR: 1.21 [1.03, 1.43] | — | Variance explained (Nagelkerke's R2*100): 0.44 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002751 | PGS000907 (PRS_MDD) |
PSS001419| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Escitalopram takers | OR: 0.96 [0.78, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002752 | PGS000907 (PRS_MDD) |
PSS001424| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Venlafaxine takers | OR: 1.14 [0.96, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.22 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002754 | PGS000907 (PRS_MDD) |
PSS001421| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Mirtazapine takers | OR: 1.23 [0.88, 1.72] | — | Variance explained (Nagelkerke's R2*100): 0.45 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002755 | PGS000907 (PRS_MDD) |
PSS001417| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Desvenlafaxine takers | OR: 1.08 [0.86, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002756 | PGS000907 (PRS_MDD) |
PSS001416| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Citalopram takers | OR: 1.19 [0.87, 1.64] | — | Variance explained (Nagelkerke's R2*100): 0.32 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002757 | PGS000907 (PRS_MDD) |
PSS001420| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Fluoxetine takers | OR: 1.01 [0.8, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002758 | PGS000907 (PRS_MDD) |
PSS001418| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Duloxetine takers | OR: 1.09 [0.87, 1.35] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002759 | PGS000907 (PRS_MDD) |
PSS001422| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Paroxetine takers | OR: 1.17 [0.86, 1.61] | — | Variance explained (Nagelkerke's R2*100): 0.3 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002760 | PGS000907 (PRS_MDD) |
PSS001223| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Sertraline takers | OR: 1.15 [1.03, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.29 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002761 | PGS000907 (PRS_MDD) |
PSS001219| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Escitalopram takers | OR: 1.16 [1.01, 1.33] | — | Variance explained (Nagelkerke's R2*100): 0.32 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002762 | PGS000907 (PRS_MDD) |
PSS001224| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Venlafaxine takers | OR: 1.19 [1.07, 1.34] | — | Variance explained (Nagelkerke's R2*100): 0.54 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002763 | PGS000907 (PRS_MDD) |
PSS001215| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Amitriptyline takers | OR: 1.16 [0.98, 1.37] | — | Variance explained (Nagelkerke's R2*100): 0.38 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002764 | PGS000907 (PRS_MDD) |
PSS001221| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Mirtazapine takers | OR: 1.08 [0.89, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002765 | PGS000907 (PRS_MDD) |
PSS001217| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Desvenlafaxine takers | OR: 1.03 [0.89, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002767 | PGS000907 (PRS_MDD) |
PSS001220| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Fluoxetine takers | OR: 1.09 [0.94, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.11 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002768 | PGS000907 (PRS_MDD) |
PSS001218| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Duloxetine takers | OR: 1.02 [0.89, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002769 | PGS000907 (PRS_MDD) |
PSS001222| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Paroxetine takers | OR: 1.09 [0.9, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.12 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002771 | PGS000907 (PRS_MDD) |
PSS001229| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Escitalopram takers | OR: 1.01 [0.89, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002772 | PGS000907 (PRS_MDD) |
PSS001234| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Venlafaxine takers | OR: 1.13 [0.97, 1.32] | — | Variance explained (Nagelkerke's R2*100): 0.2 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002773 | PGS000907 (PRS_MDD) |
PSS001225| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Amitriptyline takers | OR: 1.02 [0.73, 1.42] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002774 | PGS000907 (PRS_MDD) |
PSS001231| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Mirtazapine takers | OR: 1.13 [0.89, 1.42] | — | Variance explained (Nagelkerke's R2*100): 0.18 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002775 | PGS000907 (PRS_MDD) |
PSS001227| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Desvenlafaxine takers | OR: 1.01 [0.84, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002776 | PGS000907 (PRS_MDD) |
PSS001226| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Citalopram takers | OR: 0.95 [0.76, 1.19] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002777 | PGS000907 (PRS_MDD) |
PSS001230| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Fluoxetine takers | OR: 0.99 [0.84, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002778 | PGS000907 (PRS_MDD) |
PSS001228| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Duloxetine takers | OR: 1.08 [0.9, 1.3] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002779 | PGS000907 (PRS_MDD) |
PSS001232| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Paroxetine takers | OR: 1.47 [1.13, 1.91] | — | Variance explained (Nagelkerke's R2*100): 1.92 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002780 | PGS000907 (PRS_MDD) |
PSS001253| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Sertraline takers | OR: 1.01 [0.94, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002782 | PGS000907 (PRS_MDD) |
PSS001254| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Venlafaxine takers | OR: 1.0 [0.91, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002783 | PGS000907 (PRS_MDD) |
PSS001245| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Amitriptyline takers | OR: 0.99 [0.89, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002784 | PGS000907 (PRS_MDD) |
PSS001251| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Mirtazapine takers | OR: 1.06 [0.96, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002785 | PGS000907 (PRS_MDD) |
PSS001247| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Desvenlafaxine takers | OR: 0.99 [0.88, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002786 | PGS000907 (PRS_MDD) |
PSS001246| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Citalopram takers | OR: 1.05 [0.93, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002787 | PGS000907 (PRS_MDD) |
PSS001250| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Fluoxetine takers | OR: 1.04 [0.94, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002788 | PGS000907 (PRS_MDD) |
PSS001248| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Duloxetine takers | OR: 0.96 [0.86, 1.08] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002789 | PGS000907 (PRS_MDD) |
PSS001252| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Paroxetine takers | OR: 0.97 [0.83, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002790 | PGS000907 (PRS_MDD) |
PSS001413| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Sertraline takers | OR: 1.04 [0.97, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002791 | PGS000907 (PRS_MDD) |
PSS001409| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Escitalopram takers | OR: 1.02 [0.94, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002792 | PGS000907 (PRS_MDD) |
PSS001414| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Venlafaxine takers | OR: 1.02 [0.94, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002793 | PGS000907 (PRS_MDD) |
PSS001405| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Amitriptyline takers | OR: 1.05 [0.88, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002794 | PGS000907 (PRS_MDD) |
PSS001411| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Mirtazapine takers | OR: 1.13 [0.97, 1.32] | — | Variance explained (Nagelkerke's R2*100): 0.27 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002795 | PGS000907 (PRS_MDD) |
PSS001407| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Desvenlafaxine takers | OR: 1.05 [0.95, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002796 | PGS000907 (PRS_MDD) |
PSS001406| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Citalopram takers | OR: 1.0 [0.89, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002797 | PGS000907 (PRS_MDD) |
PSS001410| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Fluoxetine takers | OR: 1.05 [0.96, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002798 | PGS000907 (PRS_MDD) |
PSS001408| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Duloxetine takers | OR: 0.97 [0.87, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002800 | PGS000907 (PRS_MDD) |
PSS001203| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Sertraline takers | OR: 1.13 [1.04, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.29 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002801 | PGS000907 (PRS_MDD) |
PSS001199| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Escitalopram takers | OR: 1.01 [0.91, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002802 | PGS000907 (PRS_MDD) |
PSS001204| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Venlafaxine takers | OR: 1.14 [1.04, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.36 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002803 | PGS000907 (PRS_MDD) |
PSS001195| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Amitriptyline takers | OR: 1.05 [0.87, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002804 | PGS000907 (PRS_MDD) |
PSS001201| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Mirtazapine takers | OR: 1.2 [1.03, 1.39] | — | Variance explained (Nagelkerke's R2*100): 0.59 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002805 | PGS000907 (PRS_MDD) |
PSS001197| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Desvenlafaxine takers | OR: 1.04 [0.92, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002806 | PGS000907 (PRS_MDD) |
PSS001196| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Citalopram takers | OR: 0.97 [0.85, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002807 | PGS000907 (PRS_MDD) |
PSS001200| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Fluoxetine takers | OR: 1.05 [0.96, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002808 | PGS000907 (PRS_MDD) |
PSS001198| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Duloxetine takers | OR: 1.0 [0.87, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002809 | PGS000907 (PRS_MDD) |
PSS001202| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Anxiety in Paroxetine takers | OR: 1.1 [0.94, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.19 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002810 | PGS000907 (PRS_MDD) |
PSS001193| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Sertraline takers | OR: 1.04 [0.96, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002811 | PGS000907 (PRS_MDD) |
PSS001189| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Escitalopram takers | OR: 1.06 [0.96, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002812 | PGS000907 (PRS_MDD) |
PSS001194| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Venlafaxine takers | OR: 1.06 [0.97, 1.17] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002813 | PGS000907 (PRS_MDD) |
PSS001185| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Amitriptyline takers | OR: 1.02 [0.85, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002814 | PGS000907 (PRS_MDD) |
PSS001191| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Mirtazapine takers | OR: 1.25 [1.08, 1.46] | — | Variance explained (Nagelkerke's R2*100): 0.93 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002816 | PGS000907 (PRS_MDD) |
PSS001186| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Citalopram takers | OR: 1.05 [0.91, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002817 | PGS000907 (PRS_MDD) |
PSS001190| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Fluoxetine takers | OR: 1.06 [0.96, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002818 | PGS000907 (PRS_MDD) |
PSS001188| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Duloxetine takers | OR: 1.05 [0.91, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002819 | PGS000907 (PRS_MDD) |
PSS001192| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Paroxetine takers | OR: 1.19 [1.02, 1.38] | — | Variance explained (Nagelkerke's R2*100): 0.6 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002820 | PGS000907 (PRS_MDD) |
PSS001273| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Sertraline takers | OR: 1.01 [0.94, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002821 | PGS000907 (PRS_MDD) |
PSS001269| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Escitalopram takers | OR: 0.96 [0.88, 1.05] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002822 | PGS000907 (PRS_MDD) |
PSS001274| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Venlafaxine takers | OR: 1.06 [0.97, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002823 | PGS000907 (PRS_MDD) |
PSS001265| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Amitriptyline takers | OR: 1.12 [0.97, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.25 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002824 | PGS000907 (PRS_MDD) |
PSS001271| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Mirtazapine takers | OR: 1.06 [0.94, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002826 | PGS000907 (PRS_MDD) |
PSS001266| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Citalopram takers | OR: 0.98 [0.86, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002827 | PGS000907 (PRS_MDD) |
PSS001270| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Fluoxetine takers | OR: 1.02 [0.92, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002829 | PGS000907 (PRS_MDD) |
PSS001272| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Paroxetine takers | OR: 0.96 [0.82, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002831 | PGS000907 (PRS_MDD) |
PSS001429| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Escitalopram takers | OR: 1.04 [0.97, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002832 | PGS000907 (PRS_MDD) |
PSS001434| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Venlafaxine takers | OR: 1.03 [0.96, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002833 | PGS000907 (PRS_MDD) |
PSS001425| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Amitriptyline takers | OR: 1.06 [0.95, 1.19] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002834 | PGS000907 (PRS_MDD) |
PSS001431| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Mirtazapine takers | OR: 1.02 [0.93, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002835 | PGS000907 (PRS_MDD) |
PSS001427| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Desvenlafaxine takers | OR: 1.11 [1.02, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.33 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002836 | PGS000907 (PRS_MDD) |
PSS001426| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Citalopram takers | OR: 1.14 [1.03, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.4 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002837 | PGS000907 (PRS_MDD) |
PSS001430| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Fluoxetine takers | OR: 1.04 [0.96, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002838 | PGS000907 (PRS_MDD) |
PSS001428| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Duloxetine takers | OR: 1.0 [0.91, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002839 | PGS000907 (PRS_MDD) |
PSS001432| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Paroxetine takers | OR: 1.11 [0.99, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.28 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002840 | PGS000907 (PRS_MDD) |
PSS001443| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Sertraline takers | OR: 0.9 [0.75, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002841 | PGS000907 (PRS_MDD) |
PSS001439| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Escitalopram takers | OR: 1.07 [0.88, 1.32] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002842 | PGS000907 (PRS_MDD) |
PSS001444| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Venlafaxine takers | OR: 1.05 [0.84, 1.3] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002844 | PGS000907 (PRS_MDD) |
PSS001441| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Mirtazapine takers | OR: 1.21 [0.85, 1.71] | — | Variance explained (Nagelkerke's R2*100): 0.37 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002845 | PGS000907 (PRS_MDD) |
PSS001437| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Desvenlafaxine takers | OR: 0.95 [0.74, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002846 | PGS000907 (PRS_MDD) |
PSS001436| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Citalopram takers | OR: 0.87 [0.61, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.19 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002847 | PGS000907 (PRS_MDD) |
PSS001440| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Fluoxetine takers | OR: 1.16 [0.96, 1.39] | — | Variance explained (Nagelkerke's R2*100): 0.26 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002848 | PGS000907 (PRS_MDD) |
PSS001438| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Duloxetine takers | OR: 0.96 [0.75, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002849 | PGS000907 (PRS_MDD) |
PSS001442| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Paroxetine takers | OR: 1.36 [0.88, 2.1] | — | Variance explained (Nagelkerke's R2*100): 0.99 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002852 | PGS000907 (PRS_MDD) |
PSS001344| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Venlafaxine takers | OR: 1.0 [0.74, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002853 | PGS000907 (PRS_MDD) |
PSS001335| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Amitriptyline takers | OR: 1.22 [0.73, 2.04] | — | Variance explained (Nagelkerke's R2*100): 0.42 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002854 | PGS000907 (PRS_MDD) |
PSS001341| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Mirtazapine takers | OR: 1.0 [0.65, 1.52] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002855 | PGS000907 (PRS_MDD) |
PSS001337| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Desvenlafaxine takers | OR: 1.58 [1.13, 2.23] | — | Variance explained (Nagelkerke's R2*100): 2.19 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002856 | PGS000907 (PRS_MDD) |
PSS001336| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Citalopram takers | OR: 1.1 [0.7, 1.74] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002857 | PGS000907 (PRS_MDD) |
PSS001340| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Fluoxetine takers | OR: 1.34 [0.91, 1.97] | — | Variance explained (Nagelkerke's R2*100): 0.75 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002858 | PGS000907 (PRS_MDD) |
PSS001338| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Duloxetine takers | OR: 1.13 [0.75, 1.7] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002859 | PGS000907 (PRS_MDD) |
PSS001342| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Paroxetine takers | OR: 1.16 [0.69, 1.95] | — | Variance explained (Nagelkerke's R2*100): 0.22 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002860 | PGS000907 (PRS_MDD) |
PSS001363| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Sertraline takers | OR: 1.0 [0.79, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002861 | PGS000907 (PRS_MDD) |
PSS001359| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Escitalopram takers | OR: 0.91 [0.69, 1.19] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002862 | PGS000907 (PRS_MDD) |
PSS001364| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Venlafaxine takers | OR: 1.06 [0.8, 1.42] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002863 | PGS000907 (PRS_MDD) |
PSS001355| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Amitriptyline takers | OR: 0.59 [0.36, 0.98] | — | Variance explained (Nagelkerke's R2*100): 2.43 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002864 | PGS000907 (PRS_MDD) |
PSS001361| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Mirtazapine takers | OR: 0.85 [0.55, 1.3] | — | Variance explained (Nagelkerke's R2*100): 0.25 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002865 | PGS000907 (PRS_MDD) |
PSS001357| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Desvenlafaxine takers | OR: 0.8 [0.59, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.58 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002868 | PGS000907 (PRS_MDD) |
PSS001358| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Duloxetine takers | OR: 0.99 [0.71, 1.38] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002869 | PGS000907 (PRS_MDD) |
PSS001362| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Paroxetine takers | OR: 0.9 [0.53, 1.52] | — | Variance explained (Nagelkerke's R2*100): 0.11 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002870 | PGS000907 (PRS_MDD) |
PSS001353| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Sertraline takers | OR: 1.0 [0.95, 1.06] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002871 | PGS000907 (PRS_MDD) |
PSS001349| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Escitalopram takers | OR: 0.99 [0.93, 1.06] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002872 | PGS000907 (PRS_MDD) |
PSS001354| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Venlafaxine takers | OR: 1.05 [0.99, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002873 | PGS000907 (PRS_MDD) |
PSS001345| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Amitriptyline takers | OR: 1.08 [0.96, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.16 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002878 | PGS000907 (PRS_MDD) |
PSS001348| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Duloxetine takers | OR: 0.99 [0.91, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002879 | PGS000907 (PRS_MDD) |
PSS001352| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Paroxetine takers | OR: 1.0 [0.9, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002883 | PGS000907 (PRS_MDD) |
PSS001205| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Amitriptyline takers | OR: 1.08 [0.86, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002884 | PGS000907 (PRS_MDD) |
PSS001211| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Mirtazapine takers | OR: 1.05 [0.84, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002885 | PGS000907 (PRS_MDD) |
PSS001207| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Desvenlafaxine takers | OR: 1.13 [0.94, 1.37] | — | Variance explained (Nagelkerke's R2*100): 0.22 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002886 | PGS000907 (PRS_MDD) |
PSS001206| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Citalopram takers | OR: 1.39 [1.08, 1.79] | — | Variance explained (Nagelkerke's R2*100): 1.2 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002887 | PGS000907 (PRS_MDD) |
PSS001210| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Fluoxetine takers | OR: 1.03 [0.85, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002888 | PGS000907 (PRS_MDD) |
PSS001208| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Duloxetine takers | OR: 1.04 [0.87, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002889 | PGS000907 (PRS_MDD) |
PSS001212| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Paroxetine takers | OR: 1.32 [1.0, 1.75] | — | Variance explained (Nagelkerke's R2*100): 0.99 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002890 | PGS000907 (PRS_MDD) |
PSS001393| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Sertraline takers | OR: 1.24 [1.14, 1.34] | — | Variance explained (Nagelkerke's R2*100): 0.9 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002894 | PGS000907 (PRS_MDD) |
PSS001391| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Mirtazapine takers | OR: 1.09 [0.94, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002895 | PGS000907 (PRS_MDD) |
PSS001387| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Desvenlafaxine takers | OR: 1.06 [0.94, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002896 | PGS000907 (PRS_MDD) |
PSS001386| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Citalopram takers | OR: 1.06 [0.92, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002897 | PGS000907 (PRS_MDD) |
PSS001390| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Fluoxetine takers | OR: 1.12 [1.02, 1.23] | — | Variance explained (Nagelkerke's R2*100): 0.27 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002898 | PGS000907 (PRS_MDD) |
PSS001388| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Duloxetine takers | OR: 0.98 [0.86, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002899 | PGS000907 (PRS_MDD) |
PSS001392| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Paroxetine takers | OR: 1.22 [1.05, 1.42] | — | Variance explained (Nagelkerke's R2*100): 0.8 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002900 | PGS000907 (PRS_MDD) |
PSS001383| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Sertraline takers | OR: 1.15 [1.01, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.28 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002901 | PGS000907 (PRS_MDD) |
PSS001379| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Escitalopram takers | OR: 1.06 [0.9, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002902 | PGS000907 (PRS_MDD) |
PSS001384| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Venlafaxine takers | OR: 1.36 [1.18, 1.58] | — | Variance explained (Nagelkerke's R2*100): 1.35 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002903 | PGS000907 (PRS_MDD) |
PSS001375| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Amitriptyline takers | OR: 0.97 [0.75, 1.24] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002904 | PGS000907 (PRS_MDD) |
PSS001381| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Mirtazapine takers | OR: 1.11 [0.88, 1.4] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002905 | PGS000907 (PRS_MDD) |
PSS001377| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Desvenlafaxine takers | OR: 0.97 [0.78, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002906 | PGS000907 (PRS_MDD) |
PSS001376| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Citalopram takers | OR: 0.96 [0.76, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002907 | PGS000907 (PRS_MDD) |
PSS001380| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Fluoxetine takers | OR: 1.09 [0.95, 1.26] | — | Variance explained (Nagelkerke's R2*100): 0.11 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002908 | PGS000907 (PRS_MDD) |
PSS001378| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Duloxetine takers | OR: 1.11 [0.89, 1.38] | — | Variance explained (Nagelkerke's R2*100): 0.15 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002909 | PGS000907 (PRS_MDD) |
PSS001382| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide attempt in Paroxetine takers | OR: 1.22 [0.95, 1.55] | — | Variance explained (Nagelkerke's R2*100): 0.54 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002910 | PGS000907 (PRS_MDD) |
PSS001333| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Sertraline takers | OR: 0.99 [0.91, 1.09] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002911 | PGS000907 (PRS_MDD) |
PSS001329| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Escitalopram takers | OR: 0.96 [0.86, 1.07] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002912 | PGS000907 (PRS_MDD) |
PSS001334| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Venlafaxine takers | OR: 1.14 [1.03, 1.27] | — | Variance explained (Nagelkerke's R2*100): 0.31 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002913 | PGS000907 (PRS_MDD) |
PSS001325| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Amitriptyline takers | OR: 1.07 [0.88, 1.29] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002914 | PGS000907 (PRS_MDD) |
PSS001331| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Mirtazapine takers | OR: 1.03 [0.87, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002915 | PGS000907 (PRS_MDD) |
PSS001327| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Desvenlafaxine takers | OR: 1.02 [0.88, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002916 | PGS000907 (PRS_MDD) |
PSS001326| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Citalopram takers | OR: 0.95 [0.82, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002917 | PGS000907 (PRS_MDD) |
PSS001330| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Fluoxetine takers | OR: 1.05 [0.93, 1.18] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002918 | PGS000907 (PRS_MDD) |
PSS001328| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Duloxetine takers | OR: 1.04 [0.89, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002919 | PGS000907 (PRS_MDD) |
PSS001332| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Other side effects in Paroxetine takers | OR: 0.97 [0.81, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002920 | PGS000907 (PRS_MDD) |
PSS001323| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Sertraline takers | OR: 1.04 [0.89, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002921 | PGS000907 (PRS_MDD) |
PSS001319| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Escitalopram takers | OR: 1.04 [0.89, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002922 | PGS000907 (PRS_MDD) |
PSS001324| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Venlafaxine takers | OR: 0.94 [0.79, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.05 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002923 | PGS000907 (PRS_MDD) |
PSS001315| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Amitriptyline takers | OR: 1.03 [0.84, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002924 | PGS000907 (PRS_MDD) |
PSS001321| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Mirtazapine takers | OR: 1.05 [0.83, 1.33] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002925 | PGS000907 (PRS_MDD) |
PSS001317| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Desvenlafaxine takers | OR: 0.82 [0.68, 0.98] | — | Variance explained (Nagelkerke's R2*100): 0.6 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002680 | PGS000907 (PRS_MDD) |
PSS001283| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Sertraline takers | OR: 1.03 [0.95, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002683 | PGS000907 (PRS_MDD) |
PSS001275| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Headaches in Amitriptyline takers | OR: 0.96 [0.81, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.04 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002706 | PGS000907 (PRS_MDD) |
PSS001366| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Shakes in Citalopram takers | OR: 1.16 [0.98, 1.38] | — | Variance explained (Nagelkerke's R2*100): 0.32 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002714 | PGS000907 (PRS_MDD) |
PSS001301| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Mirtazapine takers | OR: 1.13 [0.9, 1.43] | — | Variance explained (Nagelkerke's R2*100): 0.2 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002719 | PGS000907 (PRS_MDD) |
PSS001302| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Muscle pain in Paroxetine takers | OR: 1.18 [0.87, 1.61] | — | Variance explained (Nagelkerke's R2*100): 0.34 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002740 | PGS000907 (PRS_MDD) |
PSS001313| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Nausea in Sertraline takers | OR: 1.08 [1.01, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.13 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002753 | PGS000907 (PRS_MDD) |
PSS001415| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Vomit in Amitriptyline takers | OR: 0.93 [0.65, 1.33] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002766 | PGS000907 (PRS_MDD) |
PSS001216| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Constipation in Citalopram takers | OR: 1.02 [0.85, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002770 | PGS000907 (PRS_MDD) |
PSS001233| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Diarrhoea in Sertraline takers | OR: 1.05 [0.94, 1.16] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002781 | PGS000907 (PRS_MDD) |
PSS001249| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Drowsiness in Escitalopram takers | OR: 0.96 [0.89, 1.05] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002799 | PGS000907 (PRS_MDD) |
PSS001412| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Trouble sleeping in Paroxetine takers | OR: 1.06 [0.92, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002815 | PGS000907 (PRS_MDD) |
PSS001187| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Agitation in Desvenlafaxine takers | OR: 1.07 [0.94, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.08 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002825 | PGS000907 (PRS_MDD) |
PSS001267| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Desvenlafaxine takers | OR: 1.02 [0.91, 1.15] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002828 | PGS000907 (PRS_MDD) |
PSS001268| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Fatigue in Duloxetine takers | OR: 0.93 [0.83, 1.04] | — | Variance explained (Nagelkerke's R2*100): 0.14 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002830 | PGS000907 (PRS_MDD) |
PSS001433| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight gain in Sertraline takers | OR: 1.02 [0.96, 1.08] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002843 | PGS000907 (PRS_MDD) |
PSS001435| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Weight loss in Amitriptyline takers | OR: 1.09 [0.67, 1.78] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002850 | PGS000907 (PRS_MDD) |
PSS001343| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Sertraline takers | OR: 1.04 [0.8, 1.36] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002851 | PGS000907 (PRS_MDD) |
PSS001339| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Rashes in Escitalopram takers | OR: 1.09 [0.79, 1.5] | — | Variance explained (Nagelkerke's R2*100): 0.07 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002866 | PGS000907 (PRS_MDD) |
PSS001356| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Citalopram takers | OR: 1.05 [0.73, 1.51] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002867 | PGS000907 (PRS_MDD) |
PSS001360| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Runny nose in Fluoxetine takers | OR: 1.03 [0.76, 1.4] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002874 | PGS000907 (PRS_MDD) |
PSS001351| European Ancestry| 1,987 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Mirtazapine takers | OR: 0.99 [0.9, 1.1] | — | Variance explained (Nagelkerke's R2*100): 0.0 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002875 | PGS000907 (PRS_MDD) |
PSS001347| European Ancestry| 2,524 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Desvenlafaxine takers | OR: 1.11 [1.02, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.34 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002876 | PGS000907 (PRS_MDD) |
PSS001346| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Citalopram takers | OR: 1.1 [1.01, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.28 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002877 | PGS000907 (PRS_MDD) |
PSS001350| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Reduced sexual desire in Fluoxetine takers | OR: 1.05 [0.98, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002880 | PGS000907 (PRS_MDD) |
PSS001213| European Ancestry| 5,719 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Sertraline takers | OR: 0.96 [0.83, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002881 | PGS000907 (PRS_MDD) |
PSS001209| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Escitalopram takers | OR: 1.03 [0.87, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002882 | PGS000907 (PRS_MDD) |
PSS001214| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Blurry vision in Venlafaxine takers | OR: 0.97 [0.84, 1.12] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002891 | PGS000907 (PRS_MDD) |
PSS001389| European Ancestry| 4,365 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Escitalopram takers | OR: 1.09 [0.99, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.15 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002892 | PGS000907 (PRS_MDD) |
PSS001394| European Ancestry| 3,967 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Venlafaxine takers | OR: 1.19 [1.09, 1.31] | — | Variance explained (Nagelkerke's R2*100): 0.63 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002893 | PGS000907 (PRS_MDD) |
PSS001385| European Ancestry| 1,657 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Suicide thoughts in Amitriptyline takers | OR: 0.94 [0.8, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.06 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002926 | PGS000907 (PRS_MDD) |
PSS001316| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Citalopram takers | OR: 1.08 [0.92, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.1 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002927 | PGS000907 (PRS_MDD) |
PSS001320| European Ancestry| 3,670 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Fluoxetine takers | OR: 1.05 [0.91, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002928 | PGS000907 (PRS_MDD) |
PSS001318| European Ancestry| 1,995 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Duloxetine takers | OR: 0.91 [0.74, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.12 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002929 | PGS000907 (PRS_MDD) |
PSS001322| European Ancestry| 1,580 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: No side effects in Paroxetine takers | OR: 0.97 [0.77, 1.22] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002950 | PGS000908 (PRS_Insomnia) |
PSS001293| European Ancestry| 5,713 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Insomnia in Sertraline takers | OR: 1.06 [0.99, 1.14] | — | Variance explained (Nagelkerke's R2*100): 0.09 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002951 | PGS000908 (PRS_Insomnia) |
PSS001289| European Ancestry| 4,362 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Insomnia in Escitalopram takers | OR: 1.12 [1.03, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.27 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002952 | PGS000908 (PRS_Insomnia) |
PSS001294| European Ancestry| 3,964 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Insomnia in Venlafaxine takers | OR: 1.03 [0.95, 1.11] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002953 | PGS000908 (PRS_Insomnia) |
PSS001285| European Ancestry| 1,655 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Insomnia in Amitriptyline takers | OR: 1.28 [1.07, 1.52] | — | Variance explained (Nagelkerke's R2*100): 1.03 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002954 | PGS000908 (PRS_Insomnia) |
PSS001291| European Ancestry| 1,986 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Insomnia in Mirtazapine takers | OR: 1.03 [0.88, 1.2] | — | Variance explained (Nagelkerke's R2*100): 0.01 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002955 | PGS000908 (PRS_Insomnia) |
PSS001287| European Ancestry| 2,523 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Insomnia in Desvenlafaxine takers | OR: 1.13 [1.03, 1.25] | — | Variance explained (Nagelkerke's R2*100): 0.38 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002956 | PGS000908 (PRS_Insomnia) |
PSS001286| European Ancestry| 2,585 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Insomnia in Citalopram takers | OR: 1.08 [0.96, 1.21] | — | Variance explained (Nagelkerke's R2*100): 0.12 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002957 | PGS000908 (PRS_Insomnia) |
PSS001290| European Ancestry| 3,665 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Insomnia in Fluoxetine takers | OR: 1.03 [0.94, 1.13] | — | Variance explained (Nagelkerke's R2*100): 0.02 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002958 | PGS000908 (PRS_Insomnia) |
PSS001288| European Ancestry| 1,994 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Insomnia in Duloxetine takers | OR: 1.14 [1.02, 1.28] | — | Variance explained (Nagelkerke's R2*100): 0.4 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM002959 | PGS000908 (PRS_Insomnia) |
PSS001292| European Ancestry| 1,577 individuals |
PGP000238 | Campos AI et al. Commun Med (Lond) (2021) |
Reported Trait: Insomnia in Paroxetine takers | OR: 1.16 [1.01, 1.33] | — | Variance explained (Nagelkerke's R2*100): 0.47 | sex, age at study enrollment, genetic PCs 1-20 | — |
| PPM007457 | PGS000926 (GBE_QT_FC1001220) |
PSS007536| African Ancestry| 6,254 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | R²: 0.02468 [0.01723, 0.03213] Incremental R2 (full-covars): -0.00089 PGS R2 (no covariates): 0.00034 [-0.00056, 0.00125] |
age, sex, UKB array type, Genotype PCs | — |
| PPM007458 | PGS000926 (GBE_QT_FC1001220) |
PSS007537| East Asian Ancestry| 1,629 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | Incremental R2 (full-covars): 0.00183 R²: 0.03667 [0.01919, 0.05415] PGS R2 (no covariates): 0.00244 [-0.00223, 0.0071] |
age, sex, UKB array type, Genotype PCs | — |
| PPM007459 | PGS000926 (GBE_QT_FC1001220) |
PSS007538| European Ancestry| 24,713 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | R²: 0.02067 [0.01717, 0.02417] Incremental R2 (full-covars): 0.00439 PGS R2 (no covariates): 0.00422 [0.00261, 0.00583] |
age, sex, UKB array type, Genotype PCs | — |
| PPM007460 | PGS000926 (GBE_QT_FC1001220) |
PSS007539| South Asian Ancestry| 7,410 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | R²: 0.0158 [0.01032, 0.02128] Incremental R2 (full-covars): 0.00236 PGS R2 (no covariates): 0.00251 [0.0003, 0.00473] |
age, sex, UKB array type, Genotype PCs | — |
| PPM007461 | PGS000926 (GBE_QT_FC1001220) |
PSS007540| European Ancestry| 67,196 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | R²: 0.02284 [0.02061, 0.02507] Incremental R2 (full-covars): 0.00532 PGS R2 (no covariates): 0.00542 [0.00431, 0.00652] |
age, sex, UKB array type, Genotype PCs | — |
| PPM007472 | PGS000929 (GBE_HC1583) |
PSS004302| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: AD all cause dementia | — | AUROC: 0.87071 [0.81635, 0.92507] | R²: 0.20833 Incremental AUROC (full-covars): 0.0113 PGS R2 (no covariates): 0.01979 PGS AUROC (no covariates): 0.61107 [0.52126, 0.70088] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007473 | PGS000929 (GBE_HC1583) |
PSS004303| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: AD all cause dementia | — | AUROC: 0.95182 [0.90381, 0.99984] | R²: 0.22288 Incremental AUROC (full-covars): 0.00617 PGS R2 (no covariates): 0.01638 PGS AUROC (no covariates): 0.54656 [0.0, 1.0] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007474 | PGS000929 (GBE_HC1583) |
PSS004304| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: AD all cause dementia | — | AUROC: 0.81502 [0.78, 0.85005] | R²: 0.12968 Incremental AUROC (full-covars): 0.00636 PGS R2 (no covariates): 0.01492 PGS AUROC (no covariates): 0.59229 [0.54215, 0.64242] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007475 | PGS000929 (GBE_HC1583) |
PSS004305| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: AD all cause dementia | — | AUROC: 0.82116 [0.74776, 0.89457] | R²: 0.1345 Incremental AUROC (full-covars): 0.00919 PGS R2 (no covariates): 0.02074 PGS AUROC (no covariates): 0.56393 [0.44983, 0.67804] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007476 | PGS000929 (GBE_HC1583) |
PSS004306| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: AD all cause dementia | — | AUROC: 0.81557 [0.79434, 0.8368] | R²: 0.11649 Incremental AUROC (full-covars): 0.02294 PGS R2 (no covariates): 0.02346 PGS AUROC (no covariates): 0.62703 [0.59629, 0.65777] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007551 | PGS000945 (GBE_HC710) |
PSS004614| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE dementia in alzheimer's disease | — | AUROC: 0.98515 [0.97381, 0.9965] | R²: 0.33632 Incremental AUROC (full-covars): 0.00807 PGS R2 (no covariates): 0.02667 PGS AUROC (no covariates): 0.7414 [0.59579, 0.88702] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007552 | PGS000945 (GBE_HC710) |
PSS004615| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE dementia in alzheimer's disease | — | AUROC: 0.8807 [0.81377, 0.94763] | R²: 0.16889 Incremental AUROC (full-covars): 0.0235 PGS R2 (no covariates): 0.04331 PGS AUROC (no covariates): 0.66609 [0.55451, 0.77766] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007553 | PGS000945 (GBE_HC710) |
PSS004616| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE dementia in alzheimer's disease | — | AUROC: 0.9584 [0.92052, 0.99629] | R²: 0.25982 Incremental AUROC (full-covars): 0.0131 PGS R2 (no covariates): 0.0675 PGS AUROC (no covariates): 0.67849 [0.36185, 0.99513] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007554 | PGS000945 (GBE_HC710) |
PSS004617| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE dementia in alzheimer's disease | — | AUROC: 0.8916 [0.86249, 0.9207] | R²: 0.16679 Incremental AUROC (full-covars): 0.05458 PGS R2 (no covariates): 0.06543 PGS AUROC (no covariates): 0.75273 [0.69847, 0.80699] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007555 | PGS000946 (GBE_HC713) |
PSS004622| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE unspecified dementia | — | AUROC: 0.82014 [0.73087, 0.90941] | R²: 0.13536 Incremental AUROC (full-covars): 0.02407 PGS R2 (no covariates): 0.01431 PGS AUROC (no covariates): 0.57071 [0.42666, 0.71476] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007556 | PGS000946 (GBE_HC713) |
PSS004624| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE unspecified dementia | — | AUROC: 0.82275 [0.77979, 0.86571] | R²: 0.12092 Incremental AUROC (full-covars): 0.00342 PGS R2 (no covariates): 0.00838 PGS AUROC (no covariates): 0.57672 [0.50856, 0.64487] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007557 | PGS000946 (GBE_HC713) |
PSS004625| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE unspecified dementia | — | AUROC: 0.90804 [0.86257, 0.9535] | R²: 0.20027 Incremental AUROC (full-covars): 0.0061 PGS R2 (no covariates): 0.0151 PGS AUROC (no covariates): 0.56115 [0.41165, 0.71066] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM007558 | PGS000946 (GBE_HC713) |
PSS004626| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE unspecified dementia | — | AUROC: 0.83545 [0.80839, 0.8625] | R²: 0.11896 Incremental AUROC (full-covars): 0.02339 PGS R2 (no covariates): 0.02543 PGS AUROC (no covariates): 0.64149 [0.59989, 0.68308] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008585 | PGS001179 (GBE_HC711) |
PSS004618| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vascular dementia | — | AUROC: 0.89609 [0.78011, 1.0] | R²: 0.23133 Incremental AUROC (full-covars): -0.00271 PGS R2 (no covariates): 0.00098 PGS AUROC (no covariates): 0.45314 [0.26337, 0.6429] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008586 | PGS001179 (GBE_HC711) |
PSS004619| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vascular dementia | — | AUROC: 0.86436 [0.80883, 0.91989] | R²: 0.14328 Incremental AUROC (full-covars): 0.00289 PGS R2 (no covariates): 0.00776 PGS AUROC (no covariates): 0.59245 [0.49395, 0.69095] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008587 | PGS001179 (GBE_HC711) |
PSS004620| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vascular dementia | — | AUROC: 0.83842 [0.72824, 0.9486] | R²: 0.14604 Incremental AUROC (full-covars): 0.00843 PGS R2 (no covariates): 0.0135 PGS AUROC (no covariates): 0.61894 [0.47358, 0.76431] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008588 | PGS001179 (GBE_HC711) |
PSS004621| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vascular dementia | — | AUROC: 0.82562 [0.78593, 0.86531] | R²: 0.10475 Incremental AUROC (full-covars): 0.00707 PGS R2 (no covariates): 0.01123 PGS AUROC (no covariates): 0.61306 [0.55366, 0.67245] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009221 | PGS001348 (GBE_HC1584) |
PSS004307| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: AD alzheimer's disease | — | AUROC: 0.96694 [0.94819, 0.98568] | R²: 0.31464 Incremental AUROC (full-covars): 0.01598 PGS R2 (no covariates): 0.04322 PGS AUROC (no covariates): 0.69389 [0.49462, 0.89316] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009222 | PGS001348 (GBE_HC1584) |
PSS004309| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: AD alzheimer's disease | — | AUROC: 0.8626 [0.81314, 0.91206] | R²: 0.15552 Incremental AUROC (full-covars): 0.03113 PGS R2 (no covariates): 0.05179 PGS AUROC (no covariates): 0.66389 [0.57085, 0.75693] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009223 | PGS001348 (GBE_HC1584) |
PSS004310| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: AD alzheimer's disease | — | AUROC: 0.91522 [0.82612, 1.0] | R²: 0.23563 Incremental AUROC (full-covars): 0.0091 PGS R2 (no covariates): 0.01731 PGS AUROC (no covariates): 0.59348 [0.39906, 0.7879] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009224 | PGS001348 (GBE_HC1584) |
PSS004311| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: AD alzheimer's disease | — | AUROC: 0.8686 [0.84242, 0.89478] | R²: 0.1517 Incremental AUROC (full-covars): 0.05292 PGS R2 (no covariates): 0.05685 PGS AUROC (no covariates): 0.72349 [0.67813, 0.76886] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009225 | PGS001349 (GBE_HC807) |
PSS004632| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE alzheimer's disease | — | AUROC: 0.96248 [0.93046, 0.9945] | R²: 0.31063 Incremental AUROC (full-covars): 0.00757 PGS R2 (no covariates): 0.03204 PGS AUROC (no covariates): 0.63583 [0.42385, 0.84781] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009226 | PGS001349 (GBE_HC807) |
PSS004634| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE alzheimer's disease | — | AUROC: 0.86841 [0.82079, 0.91602] | R²: 0.16057 Incremental AUROC (full-covars): 0.03323 PGS R2 (no covariates): 0.05188 PGS AUROC (no covariates): 0.67961 [0.58969, 0.76952] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009227 | PGS001349 (GBE_HC807) |
PSS004635| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE alzheimer's disease | — | AUROC: 0.9136 [0.8364, 0.9908] | R²: 0.24293 Incremental AUROC (full-covars): 0.00891 PGS R2 (no covariates): 0.01019 PGS AUROC (no covariates): 0.53145 [0.34417, 0.71873] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009228 | PGS001349 (GBE_HC807) |
PSS004636| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE alzheimer's disease | — | AUROC: 0.8666 [0.84246, 0.89075] | R²: 0.15418 Incremental AUROC (full-covars): 0.04665 PGS R2 (no covariates): 0.05271 PGS AUROC (no covariates): 0.71238 [0.66844, 0.75632] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM009238 | PGS001775 (PRS39_AD) |
PSS007663| European Ancestry| 532 individuals |
PGP000255 | Ebenau JL et al. Alzheimers Dement (Amst) (2021) |
Reported Trait: Other dementia (excluding all-type dementia and Alzheimer's disease) | HR: 0.5 [0.3, 0.9] | — | — | Age, sex, population substructure, Mini-Mental State Examination (predictor: APOE ε4 allele or normalized PRS, outcome: clinical progression to dementia) | — |
| PPM009237 | PGS001775 (PRS39_AD) |
PSS007663| European Ancestry| 532 individuals |
PGP000255 | Ebenau JL et al. Alzheimers Dement (Amst) (2021) |
Reported Trait: Alzheimer's disease dementia | HR: 1.7 [1.1, 2.8] | — | — | Age, sex, population substructure, Mini-Mental State Examination (predictor: APOE ε4 allele or normalized PRS, outcome: clinical progression to dementia) | — |
| PPM009509 | PGS001827 (portability-PLR_290.1) |
PSS009297| European Ancestry| 19,618 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.0455 [0.0315, 0.0595] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009510 | PGS001827 (portability-PLR_290.1) |
PSS009071| European Ancestry| 4,070 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.025 [-0.0058, 0.0558] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009511 | PGS001827 (portability-PLR_290.1) |
PSS008625| European Ancestry| 6,562 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.0324 [0.0081, 0.0565] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009512 | PGS001827 (portability-PLR_290.1) |
PSS008399| Greater Middle Eastern Ancestry| 1,186 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.0695 [0.0122, 0.1264] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009513 | PGS001827 (portability-PLR_290.1) |
PSS008179| South Asian Ancestry| 6,222 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.046 [0.0211, 0.0708] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009514 | PGS001827 (portability-PLR_290.1) |
PSS007964| East Asian Ancestry| 1,802 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.0477 [0.0013, 0.094] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009515 | PGS001827 (portability-PLR_290.1) |
PSS007745| African Ancestry| 2,441 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.0445 [0.0047, 0.0842] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009516 | PGS001827 (portability-PLR_290.1) |
PSS008849| African Ancestry| 3,852 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.0522 [0.0206, 0.0837] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009517 | PGS001828 (portability-PLR_290.11) |
PSS009298| European Ancestry| 19,563 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Alzheimer's disease | — | — | Partial Correlation (partial-r): 0.0482 [0.0342, 0.0622] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009519 | PGS001828 (portability-PLR_290.11) |
PSS008626| European Ancestry| 6,544 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Alzheimer's disease | — | — | Partial Correlation (partial-r): 0.0354 [0.0111, 0.0596] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009520 | PGS001828 (portability-PLR_290.11) |
PSS008400| Greater Middle Eastern Ancestry| 1,183 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Alzheimer's disease | — | — | Partial Correlation (partial-r): 0.0684 [0.011, 0.1254] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009521 | PGS001828 (portability-PLR_290.11) |
PSS008180| South Asian Ancestry| 6,205 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Alzheimer's disease | — | — | Partial Correlation (partial-r): 0.0283 [0.0034, 0.0532] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009522 | PGS001828 (portability-PLR_290.11) |
PSS007965| East Asian Ancestry| 1,802 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Alzheimer's disease | — | — | Partial Correlation (partial-r): 0.045 [-0.0015, 0.0912] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009523 | PGS001828 (portability-PLR_290.11) |
PSS007746| African Ancestry| 2,429 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Alzheimer's disease | — | — | Partial Correlation (partial-r): 0.0414 [0.0015, 0.0812] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009524 | PGS001828 (portability-PLR_290.11) |
PSS008850| African Ancestry| 3,836 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Alzheimer's disease | — | — | Partial Correlation (partial-r): 0.0338 [0.002, 0.0654] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009518 | PGS001828 (portability-PLR_290.11) |
PSS009072| European Ancestry| 4,062 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Alzheimer's disease | — | — | Partial Correlation (partial-r): -0.0098 [-0.0406, 0.021] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009528 | PGS001829 (portability-PLR_296.2) |
PSS008401| Greater Middle Eastern Ancestry| 1,055 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0527 [-0.0082, 0.1133] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009529 | PGS001829 (portability-PLR_296.2) |
PSS008181| South Asian Ancestry| 5,870 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): -0.0051 [-0.0307, 0.0205] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009531 | PGS001829 (portability-PLR_296.2) |
PSS007747| African Ancestry| 2,272 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): -0.0294 [-0.0706, 0.0119] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009532 | PGS001829 (portability-PLR_296.2) |
PSS008851| African Ancestry| 3,678 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0034 [-0.029, 0.0358] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009525 | PGS001829 (portability-PLR_296.2) |
PSS009299| European Ancestry| 17,764 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0323 [0.0176, 0.047] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009526 | PGS001829 (portability-PLR_296.2) |
PSS009073| European Ancestry| 3,729 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0074 [-0.0248, 0.0396] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009527 | PGS001829 (portability-PLR_296.2) |
PSS008627| European Ancestry| 5,989 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.027 [0.0017, 0.0524] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009530 | PGS001829 (portability-PLR_296.2) |
PSS007966| East Asian Ancestry| 1,742 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0274 [-0.0199, 0.0745] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009533 | PGS001830 (portability-PLR_318) |
PSS009300| European Ancestry| 19,400 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Tobacco use disorder | — | — | Partial Correlation (partial-r): 0.0557 [0.0416, 0.0697] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009534 | PGS001830 (portability-PLR_318) |
PSS009074| European Ancestry| 4,022 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Tobacco use disorder | — | — | Partial Correlation (partial-r): 0.0092 [-0.0218, 0.0401] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009535 | PGS001830 (portability-PLR_318) |
PSS008628| European Ancestry| 6,548 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Tobacco use disorder | — | — | Partial Correlation (partial-r): 0.0603 [0.0361, 0.0845] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009536 | PGS001830 (portability-PLR_318) |
PSS008402| Greater Middle Eastern Ancestry| 1,180 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Tobacco use disorder | — | — | Partial Correlation (partial-r): 0.0076 [-0.05, 0.0651] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009537 | PGS001830 (portability-PLR_318) |
PSS008182| South Asian Ancestry| 6,249 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Tobacco use disorder | — | — | Partial Correlation (partial-r): 0.0361 [0.0113, 0.0609] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009538 | PGS001830 (portability-PLR_318) |
PSS007967| East Asian Ancestry| 1,800 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Tobacco use disorder | — | — | Partial Correlation (partial-r): 0.0404 [-0.0061, 0.0867] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009539 | PGS001830 (portability-PLR_318) |
PSS007748| African Ancestry| 2,445 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Tobacco use disorder | — | — | Partial Correlation (partial-r): -0.0084 [-0.0482, 0.0314] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009540 | PGS001830 (portability-PLR_318) |
PSS008852| African Ancestry| 3,876 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Tobacco use disorder | — | — | Partial Correlation (partial-r): 0.0032 [-0.0284, 0.0347] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010331 | PGS001932 (portability-PLR_insomnia) |
PSS009419| European Ancestry| 19,978 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sleeplessness / insomnia | — | — | Partial Correlation (partial-r): 0.1248 [0.1111, 0.1384] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010332 | PGS001932 (portability-PLR_insomnia) |
PSS009193| European Ancestry| 4,116 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sleeplessness / insomnia | — | — | Partial Correlation (partial-r): 0.1003 [0.0699, 0.1305] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010333 | PGS001932 (portability-PLR_insomnia) |
PSS008747| European Ancestry| 6,626 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sleeplessness / insomnia | — | — | Partial Correlation (partial-r): 0.1093 [0.0854, 0.133] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010334 | PGS001932 (portability-PLR_insomnia) |
PSS008521| Greater Middle Eastern Ancestry| 1,153 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sleeplessness / insomnia | — | — | Partial Correlation (partial-r): 0.0776 [0.0195, 0.1353] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010335 | PGS001932 (portability-PLR_insomnia) |
PSS008299| South Asian Ancestry| 6,199 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sleeplessness / insomnia | — | — | Partial Correlation (partial-r): 0.0768 [0.052, 0.1015] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010337 | PGS001932 (portability-PLR_insomnia) |
PSS007863| African Ancestry| 2,460 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sleeplessness / insomnia | — | — | Partial Correlation (partial-r): 0.0475 [0.0078, 0.087] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010338 | PGS001932 (portability-PLR_insomnia) |
PSS008967| African Ancestry| 3,863 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sleeplessness / insomnia | — | — | Partial Correlation (partial-r): 0.033 [0.0013, 0.0645] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010336 | PGS001932 (portability-PLR_insomnia) |
PSS008076| East Asian Ancestry| 1,788 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Sleeplessness / insomnia | — | — | Partial Correlation (partial-r): 0.0473 | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010835 | PGS001995 (portability-PLR_narcolepsy) |
PSS009478| European Ancestry| 19,922 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | Partial Correlation (partial-r): 0.0959 [0.0822, 0.1097] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010836 | PGS001995 (portability-PLR_narcolepsy) |
PSS009252| European Ancestry| 4,057 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | Partial Correlation (partial-r): 0.0898 [0.0591, 0.1203] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010837 | PGS001995 (portability-PLR_narcolepsy) |
PSS008806| European Ancestry| 6,571 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | Partial Correlation (partial-r): 0.0631 [0.039, 0.0872] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010838 | PGS001995 (portability-PLR_narcolepsy) |
PSS008580| Greater Middle Eastern Ancestry| 1,078 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | Partial Correlation (partial-r): 0.0622 [0.002, 0.1221] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010839 | PGS001995 (portability-PLR_narcolepsy) |
PSS008358| South Asian Ancestry| 6,001 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | Partial Correlation (partial-r): 0.0739 [0.0487, 0.0991] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010840 | PGS001995 (portability-PLR_narcolepsy) |
PSS008135| East Asian Ancestry| 1,752 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | Partial Correlation (partial-r): 0.0367 [-0.0104, 0.0837] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010841 | PGS001995 (portability-PLR_narcolepsy) |
PSS007922| African Ancestry| 2,395 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | Partial Correlation (partial-r): 0.0267 [-0.0135, 0.0668] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM010842 | PGS001995 (portability-PLR_narcolepsy) |
PSS009026| African Ancestry| 3,750 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Daytime dozing / sleeping (narcolepsy) | — | — | Partial Correlation (partial-r): 0.0356 [0.0036, 0.0677] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011147 | PGS002035 (portability-ldpred2_290.1) |
PSS009297| European Ancestry| 19,618 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.0425 [0.0285, 0.0564] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011148 | PGS002035 (portability-ldpred2_290.1) |
PSS009071| European Ancestry| 4,070 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.0206 [-0.0102, 0.0513] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011149 | PGS002035 (portability-ldpred2_290.1) |
PSS008625| European Ancestry| 6,562 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.0343 [0.0101, 0.0585] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011150 | PGS002035 (portability-ldpred2_290.1) |
PSS008399| Greater Middle Eastern Ancestry| 1,186 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.0658 [0.0084, 0.1227] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011151 | PGS002035 (portability-ldpred2_290.1) |
PSS008179| South Asian Ancestry| 6,222 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.0453 [0.0205, 0.0701] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011152 | PGS002035 (portability-ldpred2_290.1) |
PSS007964| East Asian Ancestry| 1,802 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.0494 [0.003, 0.0956] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011153 | PGS002035 (portability-ldpred2_290.1) |
PSS007745| African Ancestry| 2,441 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.044 [0.0042, 0.0837] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011154 | PGS002035 (portability-ldpred2_290.1) |
PSS008849| African Ancestry| 3,852 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Dementias | — | — | Partial Correlation (partial-r): 0.04 [0.0083, 0.0715] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011155 | PGS002036 (portability-ldpred2_296.2) |
PSS009299| European Ancestry| 17,764 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0556 [0.041, 0.0703] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011156 | PGS002036 (portability-ldpred2_296.2) |
PSS009073| European Ancestry| 3,729 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0583 [0.0261, 0.0903] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011158 | PGS002036 (portability-ldpred2_296.2) |
PSS008401| Greater Middle Eastern Ancestry| 1,055 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): 0.0239 [-0.0371, 0.0847] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011159 | PGS002036 (portability-ldpred2_296.2) |
PSS008181| South Asian Ancestry| 5,870 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Depression | — | — | Partial Correlation (partial-r): |